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CHAPTER I 
THE ABSORPTION OF SUBCUTANEOUSLY INJECTED INSULIN 
Review and Introduction 
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INTRODUCTION 
Although diabetic patients have been treated with subcutaneously in-
jected insulin for 65 years now, surprisingly little is known about 
the process of absorption of the insulin from the site of injection. 
It must be admitted, however, that it is difficult to investigate the 
absorption process because the different methods used for this purpose 
all have their limitations. 
Binder was the first to investigate the absorption process systematic-
ally (1). Since normoglycaemia is now generally aimed at, to prevent 
the development of diabetic complications, the interest for the 
insulin absorption process has increased. To reach and maintain normo-
glycaemia it is necessary to obtain a fast and reproducible absorption 
of the injected insulin. A too slow absorption rate of insulin inject-
ed before a meal allows the blood glucose level to rise; variations in 
rate of absorption from day to day cause undesirable fluctuations in 
blood glucose level. To prevent these adverse events, knowledge about 
the factors influencing the absorption process is necessary. The 
problem of so-called brittleness (lability) of diabetes is another 
reason why it is important to study insulin absorption. This syndrome 
is characterized by different and unpredictable levels of blood glu-
cose at similar moments of different days. Both variation in absorp-
tion rate of insulin and subcutaneous degradation of insulin have been 
suggested as possible causes of this brittleness (2,3,4). 
Thus, further research of insulin absorption certainly seems justi-
fied. In this review we summarize the available data concerning insu-
lin absorption. After the review of Binder et al (5) and the thesis of 
Lauritzen (6), further studies have been done, the results of which we 
will include in this review. 
METHODS USED TO INVESTIGATE INSULIN ABSORPTION 
Before the factors influencing the absorption of insulin will be dis-
cussed, it is appropriate to deal with the methods used to investigate 
the absorption of subcutaneously injected insulin. The methods de-
scribed have been used in experimental animals, healthy volunteers and 
diabetic patients. Differences between results in healthy volunteers 
and diabetic patients have not been described. 
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The methods in use are: 
1. Excision of the injection site. The most direct method to study the 
absorption of insulin is excision of the injection site on differ-
ent moments after the injection and measurement of the residual 
amount of insulin after homogemzation of the tissues and extrac-
tion of the insulin. In man this method has only rarely been em-
ployed, but it has been used more often in experimental animals 
(1,7,8). In some species evidence was obtained for partial degra-
dation of insulin in the subcutaneous fat layer (see below). 
2. Measurement of blood glucose levels. In this method the biological 
activity of the absorbed insulin is measured. The blood glucose 
concentration is not only determined by the amount of insulin ab-
sorbed, but also by other factors, such as absorption of carbohy-
drates from the digestive tract, transport of glucose over cell 
membranes, glucose production by the liver and pharmacokinetics of 
absorbed insulin (see below). 
3. The euglycaemic clamp technique. In this procedure the blood glu-
cose level after insulin injection is kept constant by infusion of 
glucose. The amount of glucose infused is a measure for the bio-
logical effect of the injected insulin. 
4. Measurement of plasma insulin levels. After measurement of insulin 
concentrations in plasma became possible, this was used to study 
the absorption process of insulin. Theoretically, this is the best 
method, because the injected hormone is actually measured in the 
plasma. Insulin concentrations, however, are not only determined by 
the absorption process but also by other factors, such as subcuta-
neous degradation of insulin which possibly occurs, residual endo-
genous secretion of insulin as is likely to be present in healthy 
volunteers and recently diagnosed type 1 diabetics, the distribu-
tion volume of insulin and binding of insulin to receptors. More-
over, in insulin-treated patients part of the absorbed insulin will 
bind to insulin antibodies. Thus, free insulin has to be distin-
guished from antibody-bound insulin. The measurement of free 
insulin in plasma, however, is difficult to perform. 
5. Measurement of labelled insulin at the injection site. The method 
mostly used to study the absorption of subcutaneously injected in-
sulin is that described by Binder in 1969 (1). In this method the 
absorption is studied by measuring the disappearance of radioactiv-
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ity from the site of injection of 125i-iabelled insulin. The im-
portant advantage of this method is its simplicity. Three condi-
tions, however, have to be met: a) labelled insulin has to behave 
exactly as non-labelled insulin throughout the absorption process; 
b) externally measured radioactivity has to reflect the amount of 
insulin not yet absorbed; and c) labelled and non-labelled insulin 
must not be degraded during the absorption process. 
As to the first condition. Binder (1) has demonstrated that the ratio 
of labelled and non-labelled insulin in the tissue excised from the 
site of injection was the same as the ratio in the injected insulin. 
Ribel (9) studied in pigs the appearance of insulin in the blood after 
injection of mono-125i_(Tyr A14)- and mono-125i_(Tyr A19)-insulin as 
compared to non-labelled insulin. Since no differences in insulin 
levels were found, it was clear that labelled insulin does not behave 
differently from non-labelled insulin throughout the absorption 
process. Thus, labelled insulin can be used to study the absorption 
process of injected insulin. 
As to the second condition: Binder (1) found in excision experiments 
in sheep that the amount of radioactivity in tissue excised at a 
certain moment after injection did not differ significantly from the 
amount calculated for that moment. We (10) demonstrated by autoradio-
graphy that during the absorption process there is no dispersion of 
insulin in horizontal direction out of the area of measurement or in 
vertical direction towards or away from the measuring crystal, pro-
vided that the insulin is injected in a standardized way between the 
subcutaneous fat and the muscular fascia. If this dispersion had been 
present, the amount of radioactivity measured at different moments 
after injection would not have been comparable. In contrast with 
Berger (11) we found a regular, circular distribution of insulin. 
Thus, the first two conditions Binder formulated for the validity of 
this method appear to be fulfilled. 
There has been much debate concermng the third condition, absence of 
subcutaneous degradation of insulin. Therefore, we will discuss this 
item more extensively. As will be seen, it has become clear that this 
condition also is fulfilled. 
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SUBCUTANEOUS DEGRADATION OF INSULIN 
Berger et al described studies in which they injected rats (12) and 
pigs (7) with tritiated short-acting insulin, excised the injection 
sites and isolated the injected insulin from the excised tissues. This 
isolation process was carried out by homogenization of the tissue, 
dissolution with sodium-dodecylsulphate and separation by column chro-
matography. It appeared that 20!ló of radioactivity was no longer incor-
porated in intact insulin. It was concluded that at least 205» of the 
injected insulin was degraded subcutaneously. Subsequently it appeared 
from their studies in healthy volunteers that the addition of Aproti-
nin, a protease-inhibitor, to injected insulin caused an acceleration 
and increase in the appearance of insulin in the blood (13). They con-
cluded that this effect might be the result of an inhibition of local 
degradation by aprotinin. This supports the concept of subcutaneous 
degradation of insulin. Studies in the rat (14) and in healthy man 
(15) showed that intravenously infused insulin has a greater blood 
glucose lowering effect than subcutaneously infused insulin. This also 
seemed in agreement with subcutaneous degradation of insulin. Galloway 
et al. (16) calculated the bioavailability index of subcutaneously in-
jected insulin. This index is defined as the ratio between the area 
under the curve (AUC) of plasma insulin after subcutaneous injection 
and the AUC after intravenous injection. It appeared that the AUC 
after subcutaneous injection is less than after intravenous in-
jection. Their conclusion was that part of the subcutaneously injected 
insulin fails to reach the blood and that this might have been de-
graded subcutaneously. 
Subcutaneous degradation of insulin was also held responsible by 
Dandona et al. (17) for the syndrome of resistance to subcutaneously 
administered insulin. They described a group of 6 patients with a very 
high need for subcutaneously administered insulin (120 to 3000 U/day), 
who could be treated with small amounts of insulin (50 U/day), when 
given intravenously. After this publication more patients were de-
scribed with this syndrome (18,19,20,21). 
Studies of continuous subcutaneous (CSII) and continuous intramuscular 
(CIMII) infusion of insulin were performed in brittle and in stable 
diabetic patients (2,3). Unpredictable fluctuations in glucose levels 
during CSII, but not during CIMII, were found in the brittle 
patients. Insulin levels were also studied (3) and found to be as un-
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predictable as the glucose levels. In the stable patients, however, 
clear insulin peaks were measured after premeal bolus doses of insu-
lin, the glucose levels remaining stable throughout the study. The 
authors suggested a relation with subcutaneous degradation of insulin 
causing a variable absorption of insulin into the blood. This degrada-
tion would be bypassed by intramuscular infusion. 
Arguments for the existence of subcutaneous degradation of insulin 
thus come from studies with tritiated insulin in rats and pigs, from 
comparison of the hypoglycaemic effect of insulin after subcutaneous 
and intravenous administration, from patients with a syndrome of 
resistance for subcutaneously administered insulin and from studies in 
patients with a brittle form of diabetes. 
The results of other studies, however, do not confirm the importance 
of subcutaneous degradation of insulin. In contrast with Berger, who 
used tritiated insulin. Binder (1) using IZSi-nrisulin has not found 
degradation of insulin in excision experiments in sheep. Deckert et 
al. (8) also performed excision of injection sites in pigs after in-
jection of 1251-labelied insulin in pigs but failed to find evidence 
for major degradation of insulin in the subcutaneous fat layer. They 
also failed to obtain evidence supporting a promoting effect of Apro-
tinin in the absorption of insulin in man (22). Other authors (23,24) 
did find a promoting effect of aprotinin, but also demonstrated a 
simultaneous increase in local circulation in the subcutaneous fat. 
The increase and acceleration in insulin absorption by aprotinin can 
thus probably be explained by an effect on the circulation rather than 
by inhibition of subcutaneous degradation. As to the difference in 
insulin dose needed with different routes of administration: the doses 
of insulin needed per 24 hours to maintain normoglycaemia during sub-
cutaneous injection were compared with the doses during intravenous 
infusion (25,26). In these studies the dose of insulin was the same, 
regardless of the route of administration. Shahshaham and Kitabchi 
(27) saw a similar effect on plasma glucose and insulin after intra-
venous, intramuscular and subcutaneous administration of insulin in 
healthy volunteers during a follow up of 4 hours. The use of the bio-
availability index as described by Galloway et al. (16) (see above) 
has been criticized by Launtzen (6). He argues that the plasma in-
sulin concertration does not only depend on the appearance rate of in-
sulin in the plasma but also on the disappearance rate. The disappear-
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ance is probably rate-limited (28), i.e. disappearance is slower at 
higher concentrations. Disappearance after intravenous injection, 
therefore, is presumably slower than after subcutaneous injection, as 
intravenous injection causes higher plasma concentrations of insulin. 
Thus, a lower AUC after subcutaneous injection than after intravenous 
injection can be caused by a faster disappearance rate after subcuta-
neous injection. 
In the mean time, the diagnoses of unexplained brittle diabetes and 
resistance for subcutaneously injected insulin appeared to be much 
rarer than was thought previously. Schade et al. (29) described a 
study in 30 "brittle" diabetic patients referred from all over the 
United States. It was possible to establish the etiology of the 
brittleness in 29 of them. In 27 patients completely different causes 
of the brittleness, mostly unrelated to the diabetes, were found. Only 
2 patients appeared to have a syndrome of resistance for insulin ad-
ministered either subcutaneously or intravenously. The syndrome of 
resistance to subcutaneously injected insulin was extensively investi-
gated by Schade and Duckworth (30) in patients with a presumptive 
diagnosis of this syndrome. Three methods of investigation were used: 
subcutaneous injection of non-labelled insulin with subsequent 
measurement of glucose and insulin concentrations in the blood in 16 
patients and absorption studies of tritiated insulin in three patients 
and three normal controls with measurement of radioactive insulin in 
blood samples. Moreover, measurement of insulin-degrading activity was 
performed in biopsy specimens from 25 patients throughout North 
America and Europe and from 8 diabetic controls. In none of these 
studies differences were found between the patients and the diabetic 
controls and in none of the patients the diagnosis could be confirm-
ed. They concluded that the syndrome of subcutaneous resistance for 
insulin is very rare and that mis-diagnosis is common. 
So it seems that subcutaneous degradation of insulin only occurs in 
some but not in all animal species. Even if it does exist in diabetic 
patients and in healthy man, it plays only a minor role. The only ex-
ception seems to be the rare diabetic patient with a proven syndrome 
of resistance for subcutaneously injected insulin. 
Of the 3 conditions formulated by Binder even the last condition that 
has been criticized most, thus appears to be fulfilled. 
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Summarizing all data, we can conclude that the method of studying 
insulin absorption by measurement of radioactivity at the injection 
site of radioactive-labelled insulin is valid and reliable. 
MECHANISMS OF INSULIN ABSORPTION 
Although little is known about the mechanisms of insulin absorption, 
several processes involved have been recognized: dissolution of hexa-
meric insulin molecules into dimeric and monomeric molecules, diffu-
sion of insulin to the capillaries, transport of insulin over the 
capillary endothelium and subcutaneous blood flow. Binder (1) demon-
strated that insulin is absorbed directly from the injection site into 
the blood and not into the lymph vessels. Using the 133xe.Washout 
method to describe the circulation, several authors indeed found a 
linear relationship between absorption of insulin and circulation in 
the subcutaneous fat layer in resting conditions (31,32,33). More 
recent studies, however, did not confirm this linear relationship if 
the circulation was increased. Ferrannim et al. (34) found that exer-
cise causes an increase in absorption rate despite a lack of increase 
in blood flow. Others (35,36) found the linear relationship between 
blood flow and absorption in resting conditions only. In situations 
with increased circulation the absorption rate appeared to increase 
only little. If either absorption rate or circulation was varied and 
the unchanged parameter was measured simultaneously, a discrepancy 
between both parameters was always found. Apparently another mechanism 
than circulation becomes rate-limiting in situations with a higher 
circulation. 
The first model of the absorption process was designed by Binder 
(37). His hypothesis is that after injection of regular insulin (in 
which insulin is in hexamenc form), water is absorbed from the in-
jected solution, after which insulin hexamers desintégrate into mono-
m e n e molecules. These monomers will diffuse through the subcutaneous 
tissue to the capillaries and through the pores of the capillary mem-
branes into the blood. As soon as a certain rate of diffusion is 
reached, the absorption process follows an exponential course. The 
capillary pores thus become rate-limiting. In this hypothesis, the 
initial increase in relative absorption rate until a constant rate is 
reached, is explained by the diffusion process. Alternative explana-
tions may be local suppression of the microcirculation by insulin 
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itself (5) and désintégration of the hexameric molecules into monomers 
(37). The slower initial phase of absorption might also be explained 
by a mechanism of active transport with saturable kinetics. Immediate-
ly after injection this transport mechanism will be saturated because 
of the high concentrations of insulin. Only after the concentration 
has decreased, a fixed percentage of insulin can be absorbed per 
minute. In contrast with the absorption of regular insulin which is 
largely determined by désintégration of hexameric insulin molecules, 
by diffusion of insulin to the capillaries and by the subcutaneous 
blood flow, the absorption of intermediate- or long-acting insulin 
preparations is also influenced by the rate of dissolution of zinc-
and NPH-crystals. 
FACTORS INFLUENCING THE ABSORPTION OF INSULIN (Table I) 
The factors known to influence insulin absorption are discussed 
below. These have been grouped according to insulin preparation (con-
centration, volume, dose; species etc) and method of administration 
(injection technique: perpendicular to the skin or using a skinfold; 
jet injection; CSII; mixing of insulins etc). Factors originating in 
the patient (posture, exercise etc.) are grouped together and finally 
a group of miscellaneous factors is made. 
A. Insulin 
1. Insulin formulation. 
The insulin formulation has the most important influence on insulin 
absorption rate. Several insulin preparations have been developed 
that are absorbed more slowly than regular insulin and thus have a 
protracted action. Binding of insulin to a fish protein, protamine, 
resulted in NPH (isophane) insulin. The solubility of the insulin-
protamine complexes is less and the absorption therefore slower 
than that of regular insulin. Addition of a surplus of zinc to 
insulin causes polymerization or crystallization of the insulin 
molecules. The large particles first have to dissolve to be absorb-
ed. This method also causes a prolongation of the time of absorp-
tion and of the time of action. The insulin preparations obtained 
can be divided into short-acting (regular, soluble), intermediate-
acting and long-acting types, with an approximate time of action of 
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Table I Influences on insulin absorption 
Factor (numbers indicate paragraphs) Influence Effect on absorption rate 
A. Insulin 
1. insulin formulation + 
2. concentration, volume, dose + 
3. species + 
B. Method of administration 
1. injection technique 
rate of injection 
perpendicular vs oblique 
jet injection + 
pen injection 
2. mixing of insulins 
regular + zinc-insulin + 
regular + isophane (NPH) insulin 
3. CSII + 
4. site of injection + 
5. depth of injection 
higher concentration and 
larger volume—» increase 
human insulin faster than 
porcine and bovine 
increase 
loss of rapid activity 
abdomen fastest, leg slowest 
С Patient factors 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
posture 
exercise 
massage 
metabolic regulation 
plasma glucose 
ketoacidosis 
smoking 
neuropathy 
insulin antibodies 
sex 
age 
duration of diabetes 
temperature 
D. Inter-/intraindividual varia-
bi lity and subcutaneous 
blood flow 
sitting slower than lying 
increase 
increase 
low bicarbonate—>increase 
decrease 
increase 
higher temperature —»increase 
increase in circulation—> 
increase 
+ : proven influence on absorption rate. 
- : proven lack of influence on absorption rate. 
? : influence unclear or not studied. 
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0.5 - 8 hours, 1.5 - 22 hours and 4-36 hours after subcutaneous 
administration, respectively. Several mixtures of these insulins 
have been introduced by the pharmaceutical compames. The differen­
ces between the distinct intermediate- and long-acting insulins 
will not be discussed here. 
2. Concentration, volume, dose. 
Among the factors best studied are concentration, volume and dose 
of injected insulin. The absorption rate of insulin was found by 
Binder (1) to be delayed as the concentration and the volume become 
larger (1). Several authors could affirm this (38), also with 
plasma glucose and insulin levels (16). The effect of a higher con­
centration appears to balance that of a smaller volume (39,40,41). 
An initial delay of absorption was found with the usual insulin 
strength by Binder, but not when a reduced concentration or a 
larger volume was used. The finding of higher concentrations 
causing a slower initial phase has been explained by the fact that 
absorption of insulin molecules depends on the passing of a capil­
lary pore. With high local insulin concentrations the number of 
capillary pores apparently is rate-limiting (37). A local depres­
sion of microcirculation by large volumes has also been suggested 
(5). 
When CSII was used to infuse different concentrations (and thus 
volumes) of insulin, differences in plasma insulin were not found 
(40,42). Only when bolus doses were infused a slower increase in 
plasma insulin levels and decrease in glucose concentration was 
found with higher concentrations (41,43). With the same concentra­
tion a change in volume of course coincides with a change of dose. 
So, the effects of an increase in volume perhaps can also be a-
scribed to an effect of change in dose. 
Parallel to the slower absorption, an increase in volume (dose) of 
insulin prolongs the time of action of the hormone. This especially 
becomes important in intermediate- or long-acting insulins. A 3056 
decrease in insulin absorption rate was found when the dose of 
intermediate-acting insulins was increased 4 to б times (44,45). A 
threefold increase in injected NPH insulin only caused a twofold 
increase in amount of insulin absorbed in the first 24 hours (46). 
Thus, an equilibrium between injected dose of intermediate- or 
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long-acting insulin and dose absorbed per 24 hours will only 
develop after several days. 
2. Species. 
In most studies a small but significant increase in absorption rate 
was found for human regular insulin when compared with purified 
porcine insulin. The parameters studied were disappearance of 
radioactivity (47,48) and plasma-glucose and insulin levels in 
healthy volunteers and type 1 diabetics (49-52). The greater hydro-
philia of human insulin was offered as an explanation of this 
finding (53). Other investigators, however, did not find a differ-
ence in disappearance of radioactivity (54) or in plasma glucose 
and insulin levels (47,55). 
After injection of intermediate acting (NPH or lente type) insulins 
of human, porcine or bovine origin no differences in absorption 
have been found (44,47,49,54). Studies to compare semisynthetic and 
biosynthetic human insulin have not been performed. 
The small differences in absorption of regular insulins, however, 
do not seem to be of any clinical importance (56,57), although re-
cently a better postprandial control was reported after biosyn-
thetic human insulin as compared with purified porcine insulin 
(58). 
B. Method of administration of insulin 
1. Injection technique. 
Several aspects of the technique of injection have been investigat-
ed. For example, the rate of injection, when varied from less than 
3 to 30 seconds, did not seem to influence insulin absorption (38). 
Two techniques of injection differing in length of the needle and 
position of the needle in the subcutaneous tissue are commonly 
used. When the needle is inserted perpendicular to the skin surface 
a shorter needle is used, while a longer needle has to be used when 
the needle is inserted at a 45" angle into a lifted skinfold. As 
reviewed by Binder (5) no differences in absorption rate were found 
between these techniques. Heine et al. (59) found no differences in 
plasma free insulin concentrations, after injection of a mixture of 
insulins, using the perpendicular technique and the skinfold tech-
nique. 
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Another aspect of the injection technique is the use of special de-
vices designed to deliver insulin, e.g. jet injector, sprinkler 
needle and insulin pen. Insulin pumps belong to these devices, but 
differ from the others because of the continuous delivery of 
insulin. Infusion with the insulin pump will be discussed separate-
ly (see B3). Jet injectors administer insulin under high pressure 
causing a fine microjet stream to pierce the skin, without use of a 
needle. A sprinkler needle has 14 small holes in the wall instead 
of only one at the tip. Both devices deliver insulin as a multitude 
of small drops dispersed in a wider area than after conventional 
injection. As it is well known that small volumes of insulin are 
absorbed faster than larger volumes, a faster rate of absorption 
was expected after injection with these devices. Peak levels of 
free insulin indeed arose sooner and lasted shorter after jet in-
jection than after conventional injection. This applies for short 
acting (60,61) and NPH insulins (62) injected separately or in com-
bination (63). A similar acceleration of absorption was observed 
after use of the sprinkler needle as compared with a conventional 
needle (64). The subject of jet injection of insulin was critically 
discussed elsewhere (65). Studies concerning the effect of injec-
tion with a pen-device on absorption of insulin have not been 
published. 
2. Mixing of insulins. 
When mixing of short- and intermediate-acting insulins in the sy-
ringe is dealt with, a differentiation must be made between inter-
mediate-acting insulins of the NPH and the zinc type. In vitro 
studies have shown a loss of solubility of the short-acting insulin 
after mixing with zinc-insulins (66) and even after mixing with 
NPH-insulins (67). Binding of the short-acting insulin to the 
excess of zinc or protamine causes this loss of solubility. With 
different NPH-insulins different degrees of loss of solubility were 
found, probably dependent on the degree of excess of protamine that 
was -rather unexpectedly- found. The degree of binding depends on 
time, temperature (higher temperature accelerates binding) and 
mixing ratio of short- and intermediate-acting insulins. The higher 
the amount of intermediate-acting insulin the faster and more com-
plete the binding of short-acting insulin. 
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The results of in vivo experiments with mixing of short- and inter-
mediate acting insulins are equivocal. When the insulin combination 
was injected immediately after mixing, some investigators found 
plasma insulin and glucose concentrations, similar to those after 
separate injection (11). If, however, the combination was injected 
5 minutes after mixing, a significant loss of activity of the regu-
lar insulin was found when combined with zinc- but not when com-
bined with NPH-insulin. Others (16,68,69) found a very substantial 
loss of rapid activity in a combination with zinc-insulin, even 
when injection took place immediately after mixing. This loss of 
activity was even greater if the combination with zinc-insulin was 
injected 48 hours after mixing. A possible explanation (70,71) for 
these different results is the use of porcine insulins by the first 
group of investigators and of human insulins by the second group. 
It has been suggested (70) that the more hydrophilic nature of the 
human insulins accelerates the interaction between regular and 
lente-type insulins. Mixing of human insulins thus would cause an 
earlier loss of short-acting activity. A similar loss of activity 
of the regular insulin was reported in combination with NPH-insulin 
(16). The explanation probably lies in the greater excess of prota-
mine in the NPH-insulin used in this study. 
The best thing to do seems not to mix different insulin prepara-
tions in a single syringe, but to draw them into separate syringes 
and inject them sequentially through one needle. Using this tech-
nique no loss of activity of short-acting insulin was found after 
sequential injection with lente insulin (72). Explanations offered 
are rapid dispersion of the insulin through the subcutaneous tissue 
and binding of the excess zinc by phosphate from the subcutaneous 
fluid. By both mechanisms the binding of regular insulin by excess 
zinc would be prevented. 
3. Continuous subcutaneous infusion of insulin. 
Few studies have been published investigating aspects of insulin 
absorption during continuous subcutaneous infusion of insulin 
(CSII). Kraegen and Chisholm reviewed this subject (73). In CSII 
insulin is infused at a variable basal rate. Before meals bolus 
doses of insulin are administered to balance the rise in plasma 
glucose by the meal. Most pumps do not infuse insulin really conti-
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nuously, but rather in an interrupted way with a pulse interval de­
termining the basal rate. Thus, the interval between pulses is 
important. The pulse interval appears not to influence plasma glu­
cose and insulin concentrations and amount of insulin absorbed per 
hour, however, whether really continuous infusion was used or pul­
satile infusion with pulse intervals between 6 and 60 minutes 
(43,74), or even 120 minutes during infusion overnight (75). A 
plateau level of free insulin is reached after б to В hours of in­
fusion at basal rate. Thus, changes in basal rate have their effect 
only several hours later. Therefore, it was suggested (75) to 
resume CSI I with a bolus dose after an interruption, in order to 
reach the plateau level sooner. Conversely, after discontinuing the 
infusion the plasma free insulin concentration after 3 hours is 
still 60% of the plateau level. 
A very good reproducibility of the absorption rate was obtained 
with CSII in contrast with the large variability after conventional 
injections (76). This is one of the main reasons why near-normo-
glycaemia can usually be obtained by means of CSII. 
4. Site of injection. 
The site of injection has been shown to influence the absorption 
rate of subcutaneously injected insulin. The fastest absorption 
rate is obtained after injection in the abdomen, then after injec­
tion in the arm and the slowest absorption rate is found after in­
jection in leg and buttock (11,16,77,78). 
The rise in postprandial blood glucose accordingly is less after 
injection in the abdomen than in the leg (77). 
5. Depth of injection. 
Conflicting results as to the influence of the depth of injection 
have been published. Kilendorf et al (32) did not find differences 
in insulin absorption rate after injection of labelled NPH-insulin 
at depths of 5, 10 and 15 rim from the skin surface. The absorption 
rate, however, was found to be faster in lean than in obese diabe­
tics. This result seems to indicate at least some influence of 
depth of injection. Birtwell (79) found a significant correlation 
between thickness of subcutaneous fat and both disappearance of 
radioactivity from the site of injection and plasma insulin 
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levels. Others (38) found a significantly faster absorption rate 
after injection of 125i_ACtrapid at a depth of 12 mm than at 3 mm 
from the skin surface. If the depth of injection was adapted to the 
thickness of the subcutaneous fat, in order to deposit the insulin 
between fat and muscle layers and the absorption rate was compared 
with that after superficial injection, a significantly faster ab-
sorption was found after deep injection (80). The influence of the 
depth of injection probably is the consequence of the presence of 
capillary plexuses just beneath the skin and between fat and muscle 
layers. Injection in a plexus causes faster absorption of insulin 
than injection in the fatlayer itself. 
Several authors (32,81,82) found a delay insulin absorption after 
injection in lipohypertrophic sites. 
C. Patient factors 
1. Orthostatic changes. 
Sitting causes a considerable fall in insulin absorption rate from 
abdomen and thigh as compared with a supine position (83). The 
insulin absorption rate decreases in parallel with a fall in sub-
cutaneous circulation. 
2. Exercise. 
In several studies exercise only influenced insulin absorption if 
exerted by the injected limb. Only once an increase in absorption 
was reported from the (resting) leg during exercise of the arm 
(31). The number of subjects in this study was, however, very 
small. When exercising was started within 10 minutes after the in-
jection the absorption from the exercising limb appeared to be 
accelerated (12,34,83,85). If there was a greater delay between in-
jection of regular insulin and exercise, conflicting results were 
found. Kemmer et al (86), in contrast with SUsstrunk et al. (78), 
did not find an increase in insulin levels after 30 minutes of 
exercise, started 35 minutes after injection. With Monotard and 
NPH-insulins an influence on plasma insulin levels was not found 
(11) when exercise was started 2.5 hours after injection, while 
with Mixtard insulin (a mixture of regular and NPH insulins) there 
was such influence. There is no clear explanation for this influen-
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ce. With exercise an increase in absorption was found although the 
circulation did not change (34,48). As the increase in absorption 
obviously cannot be ascribed to a circulatory effect, a massaging 
effect of muscular contractions has been suggested (34). 
3. Massage. 
In healthy non-diabetics gentle massage of the injection site 
applied during 30 minutes of the first hour after injection of 
regular insulin was shown to produce significantly higher insulin 
and lower glucose levels compared with the normal resting situation 
(11,87). The same results were found in type 1 diabetics with 
massage exerted during only 3 minutes (88). 
4. Metabolic regulation. 
The absorption rate of insulin is not influenced by the plasma glu-
cose level at the moment of injection (30), but it is by the pre-
sence of ketoacidosis. Low plasma bicarbonate levels cause a twice 
faster absorption rate of NPH-insulin than bicarbonate levels in 
the normal range (32). Probably, this acceleration of absorption is 
the result of the increase in subcutaneous circulation during keto-
acidosis (89). During hypoglycaemia counter-regulatory hormones 
will cause a vasoconstriction and therefore a slower absorption 
will probably take place. However, no studies in this field are 
published. 
5. Smoking. 
Klemp et al. (90) found absorption to be slower in diabetic 
patients who smoked one cigarette 90 minutes after injection of 
insulin. This effect lasted as long as the vasoconstriction caused 
by smoking (91). Others (92) did not find differences in plasma 
insulin levels in healthy volunteers whether one cigarette was 
smoked imniediately before and after injection of insulin or not. 
6. Neuropathy. 
It was found (1) that regular insulin was absorbed faster in 
patients with a diminished sense of vibration. The explanation for 
this phenomenon is unknown. 
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7. Insulin antibodies. 
Several authors (93,94) have suggested an influence of the presence 
of insulin antibodies on the absorption rate of subcutaneously 
injected insulin. As far as we know no studies on this subject have 
been publisned. 
8. Sex, age and duration of diabetes 
Ktflendorf (32) showed that sex, age and duration of diabetes have 
no influence on the absorption rate of subcutaneously injected NPH 
insulin. 
9. Temperature. 
Taking a sauna bath (95) or a warm (42°C) bath (11) shortly after 
the injection of regular insulin was found to induce a considerably 
faster absorption of insulin. A twice faster absorption rate was 
found when the sauna bath was taken 60 minutes after the injection 
of regular insulin. A cold (22°C) bath was found to cause a signi-
ficant decrease in absorption rate (11). Insulin absorption also 
appeared to be 50% greater at a room temperature of 35°C than at 
20°C (96). This finding explains why patients travelling in warm 
countries often have to diminish their insulin dose because of un-
expected hypoglycaemias. Local application of heat or cold at the 
injection site by means of a water bottle had similar, but less 
marked effects (11,29). 
D. Miscellaneous factors 
Intra- and interpatient variability and subcutaneous blood flow 
So far, we discussed several factors known at this moment to influence 
the absorption rate of subcutaneously injected insulin. Despite stan-
dardizing these factors a large intra- and interpatient variation 
remains. Using regular insulin, the coefficient of variation for the 
half-life of radioactivity at the injection site is approximately 15% 
for the intrapatient variability and 30% for the between-patient vari-
ability (1). Using intermediate- and long-acting insulins these coef-
ficients of variation are even greater: 25% and 50% (97,98). Similar 
variations of plasma insulin concentrations were found (99). The exact 
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cause of this variability is not known, but in the resting situation 
there is a strong correlation between absorption rate and subcutaneous 
blood flow. Subcutaneous blood flow has been studied simultaneously 
with insulin absorption after injection of ^ 3 χ
θ an(j insulin through 
the same needle at the same injection site (31,32) or contralaterally 
(33). The latter technique excludes a possible mutual influence of the 
two injected substances. Very good correlation coefficients have been 
found between insulin absorption rate and subcutaneous blood flow for 
regular and protamine or lente insulins. Intra- and inter- patient 
differences in blood flow thus probably play a major part in the 
origin of the variability of insulin absorption. 
Several of the factors discussed above are known to influence the ab­
sorption rate of insulin through an effect on the subcutaneous circu­
lation. The influence of the injection site depends on differences in 
blood flow at different sites on the body (77). The influence of 
smoking, temperature and posture also has been proven to proceed 
through an effect on blood flow (90,31,83). It is less certain that 
the influence of exercise on the absorption rate is mediated by an 
effect on circulation, at least at higher levels of blood flow 
(31,34). 
For the remaining factors the contribution of the circulation is un­
known. 
SUMMARY AND AIM OF THE STUDY 
In two clinical situations knowledge of the mechanisms and clinical 
factors governing the absorption process of subcutaneously injected 
insulin is important. First, if it is tried to achieve normoglycaemia, 
as is generally done nowadays to prevent the long-term complications 
of diabetes mellitus, it is helpful to be aware of the factors in­
fluencing the absorption rate of insulin. These factors can be chosen 
to obtain an optimum availability of insulin. Secondly, variation in 
insulin absorption has been incriminated as a possible cause of the 
so-called brittleness of the metabolic regulation in type 1 diabetes. 
Because of its clinical implications it is necessary to clarify this 
possibility. 
Four methods to study the absorption process have been described, of 
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which the method of measurement of radioactivity at the injection site 
of labelled insulin is the most attractive, because of its simplici-
ty. It has recently become clear that this method is valid. 
Although the actual mechanisms of insulin absorption have not yet been 
elucidated, many clinical factors influencing the absorption have been 
described. The influence of several other factors, however, remains 
unknown. It is, for example, not clear if there are differences in ab-
sorption rate between healthy volunteers and type 1 diabetic patients, 
if there is an influence of the technique of injection, of the depth 
of injection, of the presence of insulin antibodies and of injection 
with an insulin pen, on the absorption rate of insulin. As stated 
above, it is also unknown if brittleness of metabolic regulation in 
type 1 diabetic patients is caused by a larger day-to-day variation in 
absorption rate than in stable diabetics. 
The aim of our study was to investigate the influence of the factors 
mentioned on insulin absorption and to investigate the role insulin 
absorption plays in the pathogenesis of brittle diabetes. The tech-
nique of measuring the residual radioactivity at the site of injection 
of labelled insulin was chosen and in several parts of the study com-
bined with simultaneous measurement of plasma glucose and insulin con-
centrations. By developing a standardized injection unwanted differen-
ces in injection technique were eliminated. In contrast with earlier 
studies the aim in our study was to inject insulin deep subcutaneously 
in the interface between fat and muscle layers. It was, therefore, 
necessary to measure the thickness of the skin with the subcutaneous 
fat as accurate as possible and to use an exact and reproducible 
needle length. Ultrasound measurement of the thickness of skin with 
fat layer, therefore, was developed and a technical device for in-
jection with exact depth was designed. 
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CHAPTER II 
TECHNICAL METHODS USED IN THE ABSORPTION STUDIES 
In this chapter the technical methods used in our study of the absorp-
tion process of subcutaneously injected insulin will be described. 
A standardized injection technique was developed by means of a. an 
accurate measurement of the thickness of skin and subcutaneous fat by 
ultrasound (II.1) and b. a technical device to obtain a reproducible 
depth and angle of injection (II.2) in order to allow the deposition 
of the insulin in the interface between fat and muscle layers. The 
method of measurement of 125i_iabel led insulin at the site of injec-
tion is described in II.3. 
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II.1 Ultrasound as a method to measure the thickness of skin with 
subcutaneous fat 
P.H.E.M. de Meijer*, J.M. Thijssen** and J.A. Lutterman* 
•Department of Medicine, Division of General Internal Medicine and 
**Biophysics Laboratory, Institute of Ophthalmology, University of 
Nijmegen, Nijmegen, The Netherlands. 
Ultrason Bull 1987; 15: 9-15. 
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Summary 
A study was performed to assess the accuracy of ultrasonic techniques 
for measuring the thickness of skin with subcutaneous fat. Both A- and 
B- mode echography were employed to avoid incorrect identification of 
the interface between fat and muscle tissue. This identification 
problem is due to the presence of fibrotic strands in the fat layer. 
Measurement results were corrected for the proper sound velocities in 
skin and fat separately. The results obtained in an animal (pig) expe-
riment by ultrasonic measurement were not significantly different from 
those obtained in histological sections. The results of the ultrasound 
measurements in human subjects were compared with those of caliper 
measurements (Holtain). A significant correlation between the results 
of these two measurement methods was found (correlation coefficients 
> 0.86); no systematic difference between the results of both methods 
was found. The reproducibility of the measurements-methods did not 
differ significantly. Technical problems were only met with the cali-
per method and never with the ultrasound technique. 
It is concluded that the combined use of A- and B-mode ultrasound is 
an accurate and generally applicable method to measure the thickness 
of skin with subcutaneous fat and to visualize the subcutaneous depo-
sition of drugs. 
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INTRODUCTION 
For the measurement of the thickness of skin with subcutaneous fat the 
technique with a skinfold caliper is frequently used. The thickness of 
skin with subcutaneous fat then is half the thickness of the skin-
fold. A disadvantage of this technique is that it changes the struc-
ture of the skin: taking up a skinfold may compress the tissue and 
squeeze fluid out of it. Compressibility of tissues, moreover, changes 
with age. Furthermore, it is possible that the fat is taken up only 
partly or that, on the other hand, a part of the underlying muscle is 
lifted up with the skin. Another disadvantage is, that it is not 
always possible to take a skinfold; especially in women with a thick 
layer of subcutaneous fat this may be a problem. 
Other published methods to measure the thickness of the subcutaneous 
fat are radiography of the soft tissues (Haymes 1976), computerized 
tomography (McCartney 1983, Frid 1986) and measurement of the electri-
cal conductivity in the tissues (Booth 1966). A disadvantage of radio-
graphy and computerized tomography of the soft tissues is the radia-
tion load that becomes important especially with repeated measure-
ments. The method of measuring the electrical conductivity in the skin 
layers is based on differences in electrical conductivity between fat 
and muscle. This conductivity is measured by inserting two needles in 
the tissues and passing a weak current through them. Because of the 
inconvenience for the patient this method is used very rarely. 
Ultrasound has been applied for measuring the thickness of subcuta-
neous fat in slaughter cattle since 1956 (Temple 1956). In 1965 the 
use of this method in man was described (Bullen 1965). Since then a 
few studies have been published in which the feasibility of A-mode 
ultrasound in the measurement of the subcutaneous fat layer in man was 
shown. Advantages of ultrasound are that it is a method with visual 
display that does not necessarily change the layers involved during 
the measurement and that it is not burdensome for the patient. 
Accurate measurement of the thickness of skin and subcutis is impor-
tant in the study of the absorption of subcutaneously injected insu-
lin. When injecting insulin subcutaneously in patients with insulin-
dependent diabetes mellitus, the depth of the injection possibly in-
fluences the absorption rate of the insulin (Hildebrandt 1983, Binder 
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1984). Thus, when it is tried to deposit the insulin immediately under 
the subcutaneous fat to get a rapid absorption, it is necessary to 
perform an accurate measurement of the thickness of skin and fat. 
The aim of this study, therefore, was to investigate the accuracy and 
reproducibility of A- and B-mode ultrasound, when used in combination, 
in the assessment of the thickness of the subcutaneous fat. This study 
was done as a methodological part of an extensive study on insulin ab-
sorption. 
MATERIALS AND METHODS 
a. Ultrasound technique. 
Measurements were done in healthy volunteers with a combined A- and 
B-mode device for ophthalmological use (TriscanR, Biophysic Medical 
Inc.). A-mode imaging displays a trace of echopeaks, which are caused 
by acoustic interfaces within the tissues. It is, therefore, a one-
dimensional display of reflectivity versus depth. The A-mode image was 
obtained with a lightweight 8 MHz transducer (diameter 5 mm, mass 5 
grams). The skin of the volunteers was slightly moistened with a con-
tact gel (Aquasonic 100R) and then the transducer was placed on the 
skin, directed vertically downward (Fig 1). Thus, the investigator 
A. 
Fig 1 The measuring position of the A-mode ultrasound transducer. 
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optimally directed the sound beam to the interface of fat and muscle 
tissue, which could be assessed from the maximal height of the ultra-
sound pattern obtained (Fig 2A). In doing so care was taken that the 
Fig 2 The image of the skin and subcutaneous layers obtained with 
A-mode ultrasound (A) and 
B-mode ultrasound (B). 
(S = skin, FS = fibrotic strand, F = muscular fascia, M 
muscle) 
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transducer was optimally mobile so that its full weight always pressed 
on the skin. Thus, only a slight and reproducible deformation force 
was exerted on the skin. The A-mode image was made maximally visible 
on the full width of the screen, so that after documentation on photo-
graph (PolaroidR) a twofold magnification was obtained. The intrin-
sic accuracy of this method was 0.2 mm. 
The B-mode image yields a 2-dimensional display of reflecting struc-
tures within the tissues. The displayed grey level is indicative of 
the reflectivity. B-mode images were obtained with the mechanical 
sector scanner, which contained a 10 MHz transducer (focused on 20 
mm). This scanner was partly filled with water and the front was 
covered by a thin rubber membrane. Before the transducer was applied, 
the skin was amply provided with contact gel (Fig 3) so that the skin 
Fig 3 The measuring position of the B-mode ultrasound transducer. 
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remained clearly discernible from the membrane on the B-mode echogram 
(Fig 2B). In this position the image was 'frozen' and photographed. 
The estimated accuracy of this method is 0.4 rm. 
The ultrasound device was always calibrated on a sound velocity of 
1530 m/s. As it appears from the literature that the velocity in the 
skin is 1710 m/s (Dines 1984) and in fat tissue 1436 m/s (Sehgal 
1986), the measured thicknesses of skin and fat were raised by 12% and 
lowered by 7% respectively, to correct the readings from the equip­
ment. 
b. Animal experiments. 
In order to study the reliability of the ultrasonic method we investi­
gated in 4 pigs if injected insulin was indeed deposited on a pre­
viously ultrasomcally determined depth. For this purpose 8 U of 
125i_ACtrapid insulin (specific radioactivity 26 μ Ci/mi; Novo 
Industri, Bagsvaerd, Denmark) were injected in both buttocks - after 
ultrasonic measurement of skin with subcutaneous fat on both sides -
in the interface of subcutis and muscle layer. After 30 minutes one 
area and after 120 minutes the other area of injection was excised 
(surface 10x10 cm, depth 3 cm, that is deep into the muscle layer). 
After freezing (in dry ice with methyl butane) the tissues were em­
bedded in carboxymethylcellulose and sections of 30 μ thickness were 
made. The localization of the insulin was then determined autoradio-
graphically. In the sections the thickness of skin with subcutaneous 
fat was measured (accuracy of 0.2 mm) and compared with the ultrasom­
cally measured thickness. 
с Experiments in healthy volunteers. 
Measurements were primarily done in 27 healthy volunteers (15 females 
and 12 males, mean age 30 years, range 22 to 39 years) without skin 
lesions. By holding the transducer perpendicular to a needle inserted 
under an angle of 45° a subcutaneous injection of insulin (8 U of 
Actrapid"; Novo Industri, Bagsvaerd, Denmark) was visualized with 
B-mode ultrasound by a first investigator. The exact position of the 
needle, just above the muscular layer, was also checked with the B-
mode scan. The injection itself was recorded on video tape (Fig 4A-B-
C). The ultrasonic measurements then proceeded with a B-mode recording 
and three Α-scan recordings. The images were measured by a second in-
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Fig 4 The course of a subcutaneous injection. 
A: the needle in subcutaneous position 
B: the moment of injection 
C: accumulation of fluid in the subcutaneous fat after the in-
jection. 
(Me = membrane, S = skin, F = fat, Mu = muscle, N = needle tip) 
37 
vestigator and afterwards the measurement procedure was repeated with 
the investigators exchanging roles. 
The B-mode recording was necessary to be able to identify the inter-
face between fat and muscle (see: Results). All measurements were done 
on the front of the upper leg at 1/3 from the knee. After the ultra-
sonic measurement both investigators measured the skinfold thickness 
with a caliper. The results were read by the investigator who had not 
performed the measurement itself. The Holtain skinfold caliper (Hol-
tain Ltd, Croswell, Crymmych, Pembs, U.K.) was used (Fig 5). Care was 
taken to lift the skin with one hand and to position the caliper at a 
distance of maximally 1 cm from the fingers. To investigate the repro-
ducibility of the caliper two investigators performed three measure-
ments on the above-mentioned place on left and right upper leg in 23 
healthy volunteers (11 females, 12 males, mean age 30 years, range 20 
to 49 years). 
Fig 5 Measurement with a Holtain skinfold caliper 
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Statistical methods 
Wilcoxon's rank sum test was used to assess the difference between the 
sex groups. 
Spearman's rdnk co.-relation coefficient was calculated to evaluate the 
correlation between the results of measurement with ultrasound and 
with the skinfold caliper. The intrasubject standard deviation (SD) 
was used to examine the reproducibility of measurements by the same 
investigator in the same volunteer. The reproducibility of the 
measurements by different investigators in the same volunteer was ex-
pressed in the interinvestigator SD. 
RESULTS 
a. Ultrasound technique 
Examples of images of the skin layers of man obtained by using ultra-
sound in measuring perpendicular to the skin surface are given in Fig 
2A (A-mode) and Fig 2B (B-mode). There is a clear separation between 
skin, fat and muscle layer, while the muscle fascia can also be dis-
tinguished separately. Fig 4A gives the ultrasonic image of a needle 
inserted subcutaneously, while Fig 4B shows the moment of injection. 
During and immediately after the injection an accumulation of fluid is 
seen that diffuses in the surrounding tissues within one minute (Fig 
4C). 
b. Animal experiments. 
In the excision experiment in pigs the injected insulin was found at 
the previously ultrasonically calculated place in all cases. The insu-
lin lay in a thin horizontal layer between fat and muscle layer (Fig 
6). There was a significant correlation between the thickness of skin 
with subcutaneous fat (round off to 0.5 mn) as measured in the sec-
tions and as measured previously by ultrasound (r=0.74, p<0.05). 
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Fig 6 Microscopic section of excised tissues in pig: position of the 
insulin (arrows) just above the muscular fascia (superimposed 
autoradiograph). 
с Experiments in healthy volunteers. 
In the 27 healthy volunteers the thickness of skin with subcutaneous 
fat varied from 3.2 to 20.7 mm when measured by Α-scan ultrasound and 
from 2.0 to 20.5 mm when measured with the caliper. Correction of the 
measuring results for the sound velocity in skin and fat tissue re­
sulted in a diminution of the measured total thicknesses from 0.1 mm 
in thin to 1.1 mm in thick fat layers (average value 0.4 mm, which is 
equivalent to 3%).In the male volunteers thickness was significantly 
less than in the female. In one female the skinfold did not fit the 
mouth of the caliper because of her adiposity; in four volunteers 
(three female and one male) a skinfold could be taken only with diffi­
culty because of the rigidity of the tissues. 
After correction of the ultrasound results for sound velocity no sys­
tematic difference with caliper measurement results was found. 
A good correlation was found by both investigators between measure­
ments with B-mode and A-mode ultrasound and measurement with the skin­
fold caliper. In men the correlation coefficient between thickness 
found by ultrasound (B-mode alone) and skinfold caliper was r=0.88; 
the correlation coefficient between A-mode (after orientating B-mode) 
ultrasound and skinfold also was r=0.88; in women the correlation 
coefficients were r=0.91 for B-mode and r=0.86 for A-mode. The corre­
lation coefficients between results found with B-mode ultrasound and 
the mean of the 3 measurements with A-mode were r=0.99 and r=0.98 for 
both investigators, respectively. 
40 
Technical problems were not met with ultrasound: the method appeared 
to be applicable in all volunteers. In assessing the reproducibility 
of the results with both methods after repeated measurements in the 
same volunteers an intrasubject SD of 4% was found for A-mode ultra-
sound. For the caliper intrasubject SDs of 5% and 65» were found in 2 
different sets of measurements. 
As to the reproducibility of the methods in measurements by different 
investigators: an intraindividual SD of 4% was calculated for A-mode 
ultrasound, while for the skinfold caliper values of 6% and 7% were 
found. 
DISCUSSION 
The measurement of the thickness of the skin with subcutaneous fat 
layer by means of the skinfold caliper has the practical problem that 
the structure and the thickness of the skin and subcutaneous layers 
are necessarily changed. Imaging methods, such as radiography and com-
puterized tomography, have the serious disadvantage for the patient of 
the use of ionizing radiation. This disadvantage does not apply to 
ultrasound. Therefore, the usefulness of ultrasound for the measure-
ment of the thickness of the subcutaneous fat layer was studied. The 
very accurate ultrasound scanner described above was used. The B-mode 
examination was used primarily for orientation and the A-mode for 
exact measurement. The B-mode appeared to be indispensable because 
frequently extra ultrasound patterns were found in the fat tissue that 
would have been difficult to distinguish from the interface of fat and 
muscle tissue with A-mode alone. On B-mode image these patterns clear-
ly appeared to lie in the fat tissue. These probably are fibrotic 
strands in the fat itself. Others (Booth 1966, Haymes 1976) also 
described the presence of these strands and the problem to distinguish 
them from the interface of fat and muscle. Haymes used the method of 
radiography to identify them. Booth could only identify these strands 
by inserting needles on several deeper levels and by measuring the 
electrical resistance on these levels. Using a combination of A- and 
B-mode ultrasound, as we did, considerably facilitates the identifica-
tion of the strands. 
The ultrasonica!ly measured thickness of the subcutaneous fat was va-
lidated histologically. The correlation between the thickness of the 
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subcutaneous fat measured by ultrasound and measured in the histologic 
sections was fair (r=0.74). Balta (1981) described a study in which in 
13 patients who were to undergo abdominal surgery, ultrasound measure-
ments of the thickness of the subcutaneous fat were performed. On the 
same place the incision afterwards was made. After the incision fat 
thickness was measured histologically. They found an excellent corre-
lation (r=0.99l) between the results of both measuring techniques. 
Bullen (1965) also validated these ultrasonic measuring results histo-
logically. In 13 patients the thickness of the abdominal fat was 
measured with 2 methods: with A-mode ultrasound and by means of needle 
punctions to the deep muscle fascia. They found a correlation coeffi-
cient r=0.98 between the results of these 2 methods, over a range of 3 
to 40 mm. The correlation we found is worse. The explanation probably 
is that we, in contrast with the other investigators, did not 
measure in vivo, but in histological sections. 
Good correlations were found between the results in the human subjects 
of the ultrasound measurements and of the caliper measurements (every 
r>0.86). The correlation coefficients we calculated were better than 
the coefficients Simon (1985) found at other localizations on the 
body. These varied between r=0.66 and r=0.84. 
The correction for the sound velocity we applied resulted in an adap-
tation of the ultrasonically measured thickness of approximately 0.4 
mm. We did not obtain a systematically smaller value with the caliper 
method. This is surprising because other investigators found consider-
able systematic differences when comparing caliper measurements with 
ultrasound (Bullen 1965, Booth 1966) and electrical conductivity 
measurements (Booth 1966). The caliper was found to produce results 
that were approximately 60% of those of the ultrasound and conductivi-
ty methods. Haymes (1976) found caliper readings to be about 85% of 
those of the ultrasound method. The ultrasound velocity assumed for 
the subcutaneous fat layer in one of the other papers (Bullen 1965) 
was only a few percents higher than the velocities we employed (1476 
m/s). Therefore, the mentioned systematic difference between the 
ultrasound and the caliper methods that was found in these studies 
cannot be explained by this discrepancy between the used velocities. 
Possible explanations for the absence of a systematic difference in 
our results might be the chosen site on the body of our measurements 
and a more adequate application of the caliper. The caliper was posi-
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tioned very carefully at the same place where tne ultrasound was 
used. Furthermore we took care to place the caliper as close as possi-
ble to the fingers tnat lifted the skinfold, as we found that placing 
the caliper at some distance gave worse results. 
As to the reproducibility of the measuring results Borkan (1982) re-
ported a better reproducibility by the same investigator with the 
skinfold caliper than with ultrasound. Only for localisations on the 
leg both methods appeared to be equivalent in this respect. Haymes 
(1976) found a similar reproducibility for both techniques at differ-
ent places on the body. 
These authors, however, did not study the reproducibility of the 
results of measurements by different investigators. We found for both 
techniques a comparable reproducibility of repeated measurement by the 
same and by different investigators. The reproducibility of the 
results we found with the A-mode ultrasound is somewhat better than 
that of the skinfold caliper. 
Both methods require a certain skill and experience. Besides, measure-
ment with the skinfold caliper posed some practical problems: in one 
volunteer the fat layer was too thick for the mouth of the caliper. 
Because of the toughness of the skin in four other volunteers some 
manipulation with the skin was necessary to be able to perform a good 
measurement. It was, however, possible to take and measure a skinfold 
with some pain for the patient, though. This manipulation did not in-
fluence the eventual measurement results. 
Ultrasound is very suitable to visualize the skin layers. Because of 
the dynamic character of this method it is, more than radiography and 
computerized tomography (which methods, moreover, have the disadvan-
tage of radiation load), suited to follow changes within the skin 
layers. Therefore, ultrasound is appropriate to study the subcutaneous 
injections such as of insulin and to be used for repeated measurements 
in longitudinal studies. 
CONCLUSION 
Ultrasound is a method that is, after some training, very suitable to 
measure the thickness of skin and subcutaneous fat. Combination of A-
mode ultrasound, the only method used till now, w t h B-mode makes it 
possible to identify the obtained ultrasound patterns, thereby elimin-
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ating a potential source of errors in A-mode ultrasound. In practice B-
mode alone appeared to be as accurate as A-mode or the combination of A-
and B-mode ultrasound. Because of its dynamic character this method can 
be used to check the position of the tip of the needle and to follow the 
course of the injection itself, when studying subcutaneous injections. 
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II.2 A technical device for standardized subcutaneous injection. 
A technical device was developed to allow injection of insulin in a 
standardized manner, i.e. at an angle of 45° and with an exactly de­
termined depth. An additional holder for an ultrasound probe (Triscan, 
Biophysic Medical Inc.) placed under an angle of 45° allowed ultraso­
nic visualization of the inserted needle under an angle of 90° and 
thereby visualization of the injection itself with the deposition of 
insulin in the tissue layers. 
The figure shows the perspex device with its metal strings. 
A. Holder for syringe. 
B. Ruler. 
С Holder for ultrasound probe. 
D. Adaptable strings. 
E. Syringe with (inserted) needle. 
F. Ultrasound probe. 
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The measurement of the disappearance of radioactivity from the site of 
injection of 125i-iabelled insulin. 
The absorption studies were performed with 125i_labelled human regular 
insulin (Actrapid HM), supplied by Novo Industri, Bagsvaerd , 
Denmark. The method used was first described by Binder (1). 
Measurements. 
125i_ l n s ui i n w a s drawn in a 1 ml syringe (Monoject) and, after the 
patient had been seated for at least of 30 minutes, injected through a 
0.5 χ 24 mm needle (Monoject) on the frontal side of the middle 1/3 
part of the upper leg. Right and left leg were used alternately in 
every patient. Before the injection the background radioactivity was 
measured at the injection site and at the corresponding site of the 
contralateral leg. Immediately after the injection of insulin and 
every 30 minutes thereafter, the radioactivity was measured at both 
legs. The amount of radioactivity was measured during 2 minutes and 
expressed as number of counts (see: Equipment). The number of counts 
immediately after injection (after subtraction of the activity at the 
contralateral leg) was taken to be 100%; the number of counts at every 
other time point was expressed as percentage of the initial number. 
The maximal time of action of regular insulin after subcutaneous ad­
ministration is approximately 8 hours; therefore, a study period of 8 
hours was chosen. When the number of counts was less than 2% before 
the end of the 8 hours period, the experiment was terminated. The per­
centages were plotted against time. The disappearance curves of radio­
activity were described with mathematical formulas based on different 
models for the absorption process (see Chapter III). 
The amount of insulin actually injected was calculated by subtracting 
the radioactivity remaining in the syringe and needle after the injec­
tion from that measured before the injection. These measurements be­
fore and after injection were performed in geometric standard condi­
tions with a Thallium-activated Nal scintillation crystal. The 
measurement conditions were calibrated to establish the amount of 125i 
expressed in ^Ci. The radioactivity was corrected for the physical 
decay in the period between the day of manufacturing and the day of 
injection. With the specific radioactivity at the day of manufacturing 
known, the actual number of units of insulin injected was calculated. 
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Equipment 
The measurements of radioactivity on the legs lasted 2 minutes each 
and were performed by means of a 2 χ 2 inch Thallium-activated, col-
limated, Nal scintillation crystal. The distance to the skin was 3.0 
cm. The signals were amplified by a photomultiplier and registered by 
a single channel analyzer (ICN Tracerlab). The energy window ranged 
from 20 to 70 KeV. The collimator diverged to a diameter of 3 inch 
(7.5 cm). This diameter was chosen because in previous excision ex­
periments in pigs (2) we had found that the distribution of the in­
jected insulin was restricted to an area with a diameter of 4 cm and a 
depth of 0.5 cm. In these experiments no further dispersion of insulin 
in a direction parallel to the skin had been found between 30 and 120 
minutes after injection. Similarly, no further dispersion of insulin 
had been found in a direction perpendicular to the skin. 
The crystal was mounted in a movable support: by means of a ruler a 
reproducible position of the crystal and collimator could be obtained 
in relation to the skin surface and the insulin depot. Care was taken 
to compress the skin and fat layers to the same degree in repeated 
measurements. This is necessary because the measuring results of the 
activity of an isotope are determined by the half-value layer (see 
next paragraph), and by the law of the squares of distances. 
125i_i
n s u
ii
n 
The 125i-Actrapid HM-insulin was supplied in a concentration of 40 
U/ml and radioactive concentration of approximately 3.0
 u
Ci/ml. The 
l25l-insulin tracer in this solution was prepared and characterized by 
a slight modification of a previously described method (3). The tracer 
was a mixture of mono-125i_(Tyr A14) -and mono-125i_(7y
r
 Al9)-insu-
lin. The radioimmunochemical stability of these tracer insulins has 
been shown to be very high: even after 6 months of storage at 2.80C 
98-99% of the radioactivity still present is bound by insulin anti­
bodies and thus is still integrated in the insulin molecule (3). The 
decay of a 1251-nucleus in 125i-insulin has been shown to destroy the 
immunoreactivity of the insulin molecule (3). The labelled insulin was 
used within a period of 3 months from the day of manufacture. The 
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tracer insulin has been shown to behave exactly as unlabelled insulin 
in subcutaneous absorption experiments in pigs (4). 
The physical half-life of 125i is 60.14 days; its decay passes by 
electron capture. The gaimia-spectrum emitted by 125i consists of Te-x-
rays (0.027 MeV) and of a gamma-peak of 0.035 MeV with an abundancy of 
7%, i.e. emitted in 7% of désintégrations. 
The aim in our experiments was to inject the patients with a previous-
ly chosen number of units of insulin. The amount of radioactivity in-
jected, therefore, varied between 0.9 uCi (if 12 U were injected 
shortly after the manufacturing date of the 125i insulin) and 0.05 
uCi (if 2 U were injected 3 months after manufacturing). This results 
in a variable error in the counting statistics. 
The half-value layer is defined as the thickness of a medium or tissue 
causing an attenuation of the radiation to 0.5 of the original radia-
tion and depends on the isotope concerned and the physical and chemi-
cal composition of the medium (tissue) between the radioactive source 
and the detector. If it is supposed that the linear attenuation coef-
ficient for 125i in fat tissue is 0.31 cm-1, the half value layer for 
1 2 5I in fat is 0.693/0.31=2.2 cm (5). In patients with a thick fat 
layer, the number of counts after injection of labelled insulin be-
tween fat and muscle layers, will be considerably less than after 
superficial injection in the same patients or after injection in 
patients with a thin fat layer. By expressing the radioactivity 
measured in a percentage of the initial amount of radioactivity 
measured immediately after injection, comparison of the disappearance 
curves becomes possible. 
Patients 
On the 2 days preceding the study the patients took 0.5 ml of Lugol's 
solution (an aqueous solution of approximately 5% iodide and 10% po-
tassium iodide) 3 times a day, in order to prevent the uptake of 125i 
in the thyroid. Before and after each experiment the radioactivity in 
the thyroid region was measured with a very sensitive method (minimum 
detectable amount of radioactivity 1 nCi of 125i) and compared with 
the room background, which was assessed by measuring a perspex neck 
phantom. During the experiments the patients were sitting in the same 
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room where the measurements took place. The room temperature was con­
stant at 21 0C. Exercise was not allowed. The measurements were per­
formed with the patient in supine position. 
Radiation Load* 
From excision experiments in pigs the distribution volume of subcuta-
neously injected insulin can be estimated to be 6 mm3 (area with a 
diameter of 4 cm, in a layer of 0.5 cm), the weight of which will be 
approximately б grams. The injected insulin disappears from the site 
of injection by absorption into the blood, where the biologic half-
time of insulin (tj) is 5 minutes. When insulin is degraded, 125i
 w
iii 
be set free and behave as an elemental ion (iodide). With the thyroid 
blocked, iodide will be rapidly excreted into the urine (80% within 10 
hours). Measurements in blood samples and above the thyroid did not 
show an increase in radioactivity above the background activity after 
injection of labelled insulin. 
To estimate the radiation load to the patient the MIRD-concept (6) was 
used. In this concept a distinction is made between organs into which 
the injected radioactivity will spread ("source organs") and organs 
radiated from these source organs ("target organs"). The dose received 
by diverse target organs due to the residence of radioactivity in the 
source organs is then calculated. The patient radiation load is ex­
pressed as the effective dose equivalent in Sievert (Sv). The effect­
ive dose equivalent is calculated by summation of the doses in some 
specific target organs (gonads, breasts, bone marrow, lungs, thyroid, 
bone) and in those five other target organs that receive the highest 
radiation dose. The dose to each target organ is multiplied by its own 
weighting factor. This factor depends on the relative risk of induc­
tion of fatal cancer in that organ due to radiation. The risk of in­
ducing fatal cancer after uniform total body irradiation is 1.25 χ 
10-2/Sv. The risk of inducing genetic damage leading to detriment in 
* The calculations in this paragraph were performed by Mrs. W.C.A.M. 
Buijs, MSc, Department of Nuclear Medicine, University Hospital 
Nijmegen. 
49 
the next two generations is 0.4 χ 10-2/Sv. The resulting total risk of 
1.65 χ 10"2/Sv can be considered as composed of the risks of the indi­
vidual organs. The relative risks of these organs are given by weight­
ing factors, which are summed up to a factor 1. 
For the MIRO calculations, knowledge of the time of residence (i.e., 
the product of time and accumulated fraction of the administered dose) 
of radioactivity in the source organs is needed. The dose in the 
target organ is then calculated by multiplication of the time of resi­
dence in the source organ and the so-called S-factor (energy absorbed 
into the target organ per unit of mass, due to the radiation from the 
source organ) and by summation of the products over all source 
organs. The S-factors are known for combinations of 20 target and 20 
source organs for 122 radionuclides. 
The following assumptions and calculation steps are formulated: 
The total activity of 125i iS successively distributed in the site of 
injection, the insulin pool and the blood pool. Physical decay during 
the time of residence can be neglected. 
In resting conditions the disappearance of 125i_iabelled human regular 
insulin from the injection site has a half-value time (tj) of approxi­
mately 3 hours. Assuming a mono-exponential disappearance and no phy­
sical decay of 1251, the time of residence is 1.44x3=4.32 hours. 
The injection site can be considered as source- and as target organ. 
The contribution of radiation emitted from the activity in this source 
organ to other organs (such as the gonads) is neglected. Because the 
distribution volume (mass) of 125i at the injection site is about 6 
grams, i.e. approximately equal to the mass of the ovaries of the 
adult woman, the MIRD S-factor for source ovary to target ovary is 
used (for 125i this is 5.4 χ IO - 3 rad/yCi.hr). The weighting factor of 
the injection site for the effective dose equivalents is taken 0.06. 
After appearance in the blood the insulin will be distributed in the 
total insulin pool (70 kg). The t| of insulin in the blood is 5 min­
utes (0.1 hr). 
After the degradation of the 125і_і
П 5 иіі П э 125i wiii circulate in the 
blood pool, from which it disappears into the urine with an effective 
t£ of 10 hours. 
The total time of residence in the whole body is thus, assuming mono-
exponential disappearance, 1.44 χ (0.1 + 10)= 14.5 hours. The total 
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body (including gonads) is source and target in this respect. The S-
factor of total body-source to total body-target for 125i is 1.7 χ 
10-6 rad/pCi.hr. 
The dose at the injection site is, after subcutaneous injection of 1 
Ci ofl25i_i
nsu
-|i
n>
 4.32 χ 5.4 χ ю-З = 2.3 χ IO - 2 rad, which is equi­
valent to 2.3 χ Ю - 4 Gray (Gy). The dose in the total body is 14.5 χ 
1.7 χ 10-6 = 2.5 χ IO - 5 rad. This is equivalent to 2.5 χ IO - 7 Gy, the 
weighting factor being 1. 
The dose to the bladder wall of 1 uCi of circulating unbound 125i is 
2.3 χ 10-6 Gy, assuming a voiding interval of 2 hours (7). This dose 
can be neglected in relation to the dose at the injection site (same 
weighting factor). The effective dose equivalent due to injection of 1 
Ci of 125l-insulin in the upper leg is 0.06 χ 2.3 χ IO"4 + 2.5 χ Ю - 7 
= 1.4 χ 10-5 Sv. 
Comparing this effective dose equivalent with that due to naturally 
occurring background radiation (4 χ 10-6 Sv/day), injection of 1 vCi 
l25l-insulin thus causes the same radiation as the natural background 
radiation during 4 days. The risk of genetic damage or radiation-in­
duced cancer due to this study is 1.4 χ ΙΟ"5 χ 1.65 χ 10-2 = 2 χ ΙΟ - 7, 
which means an extra risk to the participants of 1 in 5 million. 
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CHAPTER III 
A COMPARISON OF 3 MATHEMATICAL MODELS TO DESCRIBE THE DISAPPEARANCE 
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Summary 
The absorption of insulin in constant and varied volumes and concen-
trations was studied in healthy volunteers. Disappearance curves of 
radioactivity after subcutaneous injection of labelled insulin were 
fitted with 3 models, a diffusion rate-limited, a dissolution rate-
limited and a capacity-limited model. For each curve and model good-
ness of fit (Ri) and sum of weighted squared deviations (SWSD) were 
calculated. With constant volume and concentration R2 was >0.97 in 
each curve. SWDS's with the second model were less satisfying than 
with the first (NS) and third (p<0.01). When volume and concentration 
were varied, the parameters of the first and third model also varied, 
arguing against the validity of these models. It is concluded that 
each of the 3 models, although yielding a good description of the ob-
served data is too simple conceptually. Suggestions for more appro-
priate modelling are discussed. 
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INTRODUCTION 
The absorption of subcutaneously injected insulin has often been 
studied with the method described by Binder (1969). In this method 
125i_iabelled insulin is injected subcutaneously and the residual 
amount of radioactivity is measured subsequently at several time 
intervals after the injection. The rate of disappearance of radio-
activity from the injection site is taken as a measure for the absorp-
tion of insulin. The conditions that have to be met for this method to 
be valid have been formulated by Binder. It has by now become clear 
that these conditions are fulfilled (1). The disappearance curves of 
radioactivity obtained with this method are characterized by a slow 
initial phase of approximately 2 hours and a subsequent faster phase. 
The initial phase appears to depend on volume and concentration of the 
injected insulin (2). 
A mathematical description of the absorption curves is useful to com-
pare the rate of absorption in different groups of patients and after 
injection with different techniques, as well as to assess the repro-
ducibility of the absorption process. Until now the absorption curves 
have mostly been characterized by the T50, i.e. the time until half of 
the radioactivity has disappeared, or the t of the log-linear phase 
of the curves. The value of these parameters is limited, because they 
do not take into account the cause and the duration of the initial 
phase. 
Several mathematical models, all of them based on diffusion rate-
limited transport, have been developed to predict plasma insulin con-
centrations after subcutaneous injection (3,4,5,6) but the actual pro-
cesses involved remain largely unknown. Comparison of kinetic models 
based on different concepts of the absorption process might contribute 
to a better understanding of the mechamsms involved. In this study 
two new concepts are introduced in order to compare them with an 
existing model of diffusion rate-limited insulin absorption (5). 
The aim was to investigate which of these three mathematical models, 
i.e. a diffusion rate-limited, a dissolution rate-limited and a capa-
city-limited model, gives the best fit to the disappearance curves and 
to discuss arguments for and against each of these models. As it has 
been found (de Meijer et al, unpublished observations) that insulin 
absorption is not different between healthy volunteers and patients 
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with uncomplicated type 1 diabetes, the studies were done in healthy 
subjects. 
MATERIALS AND METHODS 
Study protocol 
a. The absorption process was studied after injection of insulin in a 
standard volume and concentration in 12 healthy volunteers. At 
09.00 h they were injected deep subcutaneously with 8 U of 125i_ 
Actrapid HM-insulin (concentration 40 U/ml, specific radioactivity 
3.0 мСі/ml; Novo Industri, Bagsvaerd, Denmark). The injection was 
given in the middle third part of the upper leg in a standardized 
way by the same investigator, aiming at deposition of the insulin 
in the interface between fat and muscle layer. To this end the 
thickness of the subcutaneous fat was previously measured by ultra­
sound (Triscan, Biophysic Medical Ine) or skinfold caliper (Holtain 
Ltd, Croswell, UK) (7). An individual needle length was chosen 
accordingly. The amount of radioactivity at the injection site was 
measured immediately after the injection and every 30 minutes 
thereafter during a total period of 8 hours. The measurements 
lasted 2 minutes each and were performed by means of a 2x2 inch 
Thallium-activated Nal scintillation crystal, with a collimator 
diameter of 3 inches (7.5 cm). The counts measured were converted 
into units of insulin, using the number of counts measured imme­
diately after injection and the actual number of units injected. 
The volunteers took 0.5 ml of Lugol's solution three times a day on 
the 2 days before the study in order to prevent accumulation of 
radioactivity in the thyroid. 
b. In 2 groups of 6 healthy volunteers the influence of concentration 
and volume of the injected insulin was studied after injection of 
12 U of insulin in one and 2 U of insulin in the other leg. In the 
first group the volume was kept constant (0.3 ml) and the concen­
tration was varied (40 U/ml vs 6.6 U/ml). In the second group the 
concentration was kept constant (40 U/ml) and the volume was varied 
(0.05 ml vs 0.3 ml). The same protocol as described above was 
followed. 
All of the subjects gave their informed consent. The hospital ethi­
cal coimittee approved of the protocols. 
56 
Subjects 
The absorption studies were done in 2 groups of healthy volunteers, of 
whom Table I summarizes some characteristics. 
Exclusion criteria were: age below 18 and beyond 50 years, obesity, 
diabetes or previous insulin injections, other medications and lesions 
of skin or subcutaneous fat. 
Table I Characteristics of volunteers participating in the study. 
sex (M:F) 6:6 7:5 
age (yr) 29.1+8.7 31.1+ 4.2 
weight (kg) 70.0+9.6 71.3+9.4 
length (cm) 175.7+9.6 180.0+ 8.6 
body mass index (kg/m2) 22.6+1.6 21.9+1.9 
ultrasonic thickness of 
subcutaneous fat (mm) 9.5+3.6 
thickness of skinfold (mm) 17.8+8.5 20.9+11.5 
needle length (mm) 11.7+4.8 14.3+ 6.9 
values expressed as mean + SD 
Pharmacokinetic models 
The disappearance curves of radioactivity from the injection site were 
described by formulas based on the following 3 models. 
1. The diffusion rate-limited model. The subcutaneous space in which 
the insulin is injected can be thought of as composed of 2 compart-
ments. The first compartment is the space into which the insulin is 
injected and the second that into which insulin diffuses and from 
which the absorption into the blood takes place (5). As a certain 
57 
amount of insulin is said to be degraded in the subcutaneous 
tissue, a rate constant for this degradation (which is assumed to 
take place in both compartments) is introduced. The formula used 
for this model was 
Uo.(ksp.e-(kd+ki2)t . kip-e-^d+kspit 
U(t) = 1 (eq. 1) 
ksp - ki2 
In this formula U(t) is the residual number of units at a certain 
time t and UQ the injected number of units. K12 is the rate con-
stant for diffusion from the first to the second compartment, kjd 
the rate constant for the absorption from the second compartment 
into the plasma and k<j the rate constant for the subcutaneous de-
gradation. 
2. The dissolution rate-limited model. This model is based on the cube 
root law. This law states that the rate of deliverance of an injec-
ted substance is determined by its volume (8). Usually it is 
assumed that the volume has a spherical shape and that the deliver-
ance only takes place at the surface of the sphere. As, however, 
the injected insulin distributes in the subcutaneous tissue along 
preexisting tissue planes, the formula for a spherical volume does 
not apply. We have found the injected insulin to distribute m a 
coin-shaped area (9). Assuming a constant relation between diameter 
and thickness of the coin, the following formula was used: 
U(t) = (Uol/3 - ki.t)3 + Urest (eq.2) 
The parameter Urest appeared to be necessary in the formula in 
order to obtain a satisfactory description of the last part of the 
measured curves. 
3. The capacity-limited model. 
The transport of some drugs is a saturable process, i.e. the 
transport rate of the drug is not proportional to its concentra-
tion, except for very small concentrations. With increasing concen-
tration the transport rate reaches a certain maximum value (Tmax 
in eq.3). 
58 
The formula for nonlinear insulin decay following Michaelis-Menten 
kinetics is: 
dU _ Тщах ( U-U
r
est)/V 
dt K
m
 + (U-U
r
est)/V (eq.3) 
In this equation dU is the rate of decline of the drug at time t, 
Tmax the maximum transport rate of the process, K
m
 the 
Michaelis-Menten constant, U the injected amount of insulin in 
units, and V the injected volume. In this formula it also was ne­
cessary to include a term U
r e
st to obtain a satisfactory fit of 
the last part of the curve. 
Statistical analysis 
Results are given as mean +_ standard deviation (SD), unless stated 
otherwise. The curve-fitting was performed by means of the computer-
program NONLIN (10). The data were weighted reciprocally (l/U^). The 
measured value at time zero, iimediately after the injection, was used 
to convert the number of counts measured into units of insulin present 
at the injection site. The number of units injected was known exactly 
by measurement of the radioactivity in the syringe before and after 
injection. In the fitting procedure the number of units at time zero 
was treated as a measured value: the curve did not necessarily have to 
fit this point. The goodness of fit of each of the mathematical 
formulas to the data was evaluated through the deviations between 
observed and model-predicted values, as R2=1 - z(Dev) 2^(Obs)2, where 
l(Dev)2 is the sum of squared deviations and E(0bs)2 i
s
 the corrected 
sum of squared observations. The sum of weighted squared deviations 
(SWSD) was calculated for each curve. For comparison of the SWSO's 
between the models Wilcoxon's signed rank test was used, after correc­
tion for the degrees of freedom if the number of parameters was 
different. 
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RESULTS 
a. Constant volume and concentration. 
The mean (_+ SD) of the parameters resulting from the curve-fitting 
procedures is shown in Table II. A representative example of the 
fitting results with each of the 3 models is given in Figure 1. 
Insulin (units) 
20 
Fig. 1: 
A representative example of the data analysis according to the 3 
models in one patient after subcutaneous injection of 12 (upper curve) 
and 2 (lower curve) units of regular insulin both in a volume of 0.3 
ml. a. Diffusion rate-limited model, b. Dissolution rate-limited 
model, с Capacity-limited model. 
The goodness of fit, expressed in the coefficient of determination 
R2, was >0.97 in every curve with each of the models. With the 
diffusion rate-limited model R 2 was 0.997+0.003 (mean + SD), with 
the dissolution rate-limited model R 2 was 0.993+0.006 and with the 
capacity-limited model (Michaelis-Menten) R 2 was 0.997+0.002. The 
SWSD was 0.072+0.085 (mean +_ SD) for the diffusion rate-limited 
model, 0.057^0.062 for the dissolution rate-limited model and 
0.028+0.019 for the Michaelis-Menten model. The capacity-limited 
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model was significantly better than the dissolution rate-limited 
model (p<0.01) and also better than the diffusion rate-limited 
model, although not reaching the 5% level of significance 
(0.05<p<0.10). There was no significant difference between the 
dissolution rate-limited and the diffusion rate-limited models 
(p>0.30). 
b. Volume and concentration varied. 
A volume with a lower concentration appeared to be absorbed faster 
than the same volume with a higher concentration. A smaller volume 
of insulin also was absorbed faster than a larger volume with the 
same concentration. The mean (_+ SD) of the parameters obtained with 
the fitting procedures is given in Table II. Variation of concen-
tration or volume both cause changes in the parameters. The good-
ness of fit, expressed in the coefficient of determination R 2 , was 
with the diffusion rate-limited model >0.94 in all but one of the 
curves ( R 2 = 0 . 8 9 6 ) . With the dissolution rate-limited model R2 was 
>0.93 in all but one of the curves ( R 2 = 0 . 9 0 0 ) , and with the 
Michaelis-Menten equation R2 was >0.98 in each curve, except for 
one ( R 2 = 0 . 9 4 7 ) . It should be mentioned that in these analyses it 
was not the same curve for which the lowest R2 was calculated. If 
the SWSD's for each of the models were compared, the Michaelis-
Menten formula always was better than the dissolution rate-limited 
model (p=0.05). With a volume of 0.3 ml and with concentrations of 
6.6 U/ml and 40 U/ml the Michaelis-Menten formula also was better 
than the diffusion-rate limited model (p=0.05), which in turn was 
better than the dissolution rate-limited model (p=0.05). 
Table II 
Parameters (mean ¿SD) calculated with the diffusion rate-limited model, the dissolution rate-limited model and the capacity-limited 
model after subcutaneous Injection of regular Insulin in constant (con) or varied (var) volume (V) and concentration (C). 
The units of insulin actually injected are given between brackets (mean +_ SD) 
diffusion rate-limited model 
ki2 kSp kd UQ 
(h-1) (h-1) (h-1) (U) 
dissolution rate-limited model 
Kl Urest UQ 
(Ul/3h-l) (U) (U) 
capacity-limited model 
Tmax Km Urest UQ 
(Uh-1) (Uml-1) (и) (y) 
V=con, Ocon 
0.2ml, 10 U/ml 0.6+0.4 0.31+0.16 0.08+0.05 β.IjMJ.S 0.15+0.03 0.2+0.2 8.5*0.7 2.2+0.8 20^15 0.5+0.3 9 4+0 5 
( 8 . 1 + 0.5 U) 
V^con, C=var 
О.ЗтІ. 40 U/ml 0.7+0.3 0.6+0.2 0.04+0.04 12.6+0.5 0.22+0.07 0.19+0.14 14.0+0.7 3.7+1.6 12+7 0.6+0.5 13.4+0.5 
(12.6+0.4 U) 
0.3ml, 6.6 U/ml 1.9+2.0 0.9+0.6 0.02+0.01 2.3+0.5 0.16+0.02 0.11+0.05 2.3+0.5 1.1+0.4 4+2 0.1+0.04 2.4+0.5 
(2.2+0.5 U) 
V=var, Ocon 
0.3ml, 40 U/ml 0.6+0.2 0.7+0.5 0.05+0.06 11.5+0.5 0.23+0.08 0.14+0.12 13.2+1.0 3.3+1.3 10+4 0.5+0.4 12.3+0.7 
(11.5+0.4 U) 
0.05ml, 40 U/ml) 0.8+0.3 0.5+0.6 0 . 2 + 0 . 2 2.3+0.8 0.14+0.04 0.08+0.03 2.3+0.9 0.9+0.4 2 3 4 2 0.08+0.05 2.3+0.8 
(2.2+0.8 U) 
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DISCUSSION 
The log-linear disappearance curves of 125i-iabelled regular insulin 
from the injection site are characterized by a slow initial phase fol-
lowed by a faster second phase. Many of the curves also show a slow 
terminal phase. This terminal phase does not seem to be clinically 
important as it only is concerned with the last percents of the injec-
ted insulin. The initial phase, however, is important as its course 
might give an indication of the local processes involved in the ab-
sorption. This phase has been shown to depend on volume and concentra-
tion of the insulin preparation (2). Several possible explanations 
have been suggested for the initial phase, as for example local vaso-
constriction at the site of injection (11), dissociation of the in-
jected insulin hexamers into dimers and monomers (12,13) and diffusion 
of insulin from the site of injection to the capillary surface and 
through the capillary pores (11). 
The fitting of the disappearance curves in this study was performed 
with three models. The cube root law was used, because the curves can 
be regarded as resulting from the dissolution of an injected dose with 
a coin-shaped volume. A 2-exponential model was chosen to describe the 
diffusion concept. The Michaelis-Menten model finally describes satur-
able processes of drug transport. This model, as far as we know, has 
not yet been used in the study of the absorption of subcutaneously in-
jected insulin. 
All three models fit well to the data. The goodness of fit of the 
Michael is-Menten formula appears to be better than that of the other 
two models, of which the diffusion rate-limited model in turn is 
better than the dissolution rate-limited model. 
A previously described model for a diffusion rate-limited process was 
chosen in unchanged form (5). This model contains a rate constant for 
subcutaneous degradation. In the other formulas inclusion of such a 
constant appeared not to be necessary to obtain a reasonable fit to 
the data. Although these two models were chosen in as simple a form as 
possible, introduction of a rest value appeared to be necessary to 
obtain a close fit to the data. This rest value is thought to be the 
mathematical representation of a small fraction of insulin remaining 
at the injection site during a longer time period. In the diffusion 
rate-limited model a rest value would have been valuable to describe 
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the slow terminal phase. It was not introduced, however, as this would 
not only have meant a change in the chosen model, but also the intro-
duction of a fifth parameter where the other formulas only have four. 
It has previously been suggested that the absorption process of insu-
lin can be considered as depending on radius and height of its coin-
shaped volume (14). Using this model it was possible to predict that 
the absorption of similar doses of U-100 and U-40 insulin, i.e. 
different volumes and concentrations, would not differ. It appears, 
however, that the cube root law gives the least satisfying fit to our 
data. The initial phase especially, could not adequately be described 
with this model. The dissolution rate-limited model apparently is a 
too simple concept to describe the absorption process. The diffusion 
rate-limited model and the capacity-limited model both fitted better 
to the data. A formula based on a 2-compartment model can describe the 
absorption process of subcutaneously injected or infused insulin, when 
studied at the resulting plasma insulin concentrations (5). A similar 
model can also explain the initial phase of disappearance of labelled 
insulin by diffusion of insulin from the first to the second compart-
ment. In our study, however, the initial phase probably is not caused 
by diffusion from a first to a second compartment. Both compartments 
are assumed to be situated in the subcutaneous fat layer. It has been 
shown that labelled insulin does not diffuse to outside the collimator 
diameter (9). The radioactivity in both compartments therefore will be 
measured simultaneously. The capacity-limited (Michaelis-Menten) model 
is an attractive alternative, because it can explain the initial phase 
as resulting from a saturable transport. It has indeed been described 
that insulin is transported across endothelial cells by a receptor-
mediated mechanism (15,16), although in the former study this 
transport was found to be unidirectional from the interior to the 
exterior of the capillary. 
In order to obtain a further argument for the Michaelis-Menten model, 
the concentration and volume of the injected insulin were varied. In-
sulin doses with a smaller volume and those with a lower concentration 
appeared to be absorbed with a faster relative absorption rate than 
larger volumes and higher concentrations. This is in agreement with 
earlier observations (2). This influence of volume and concentration 
could mean an argument for the Michael is-Menten type of saturable 
kinetics. The calculated parameters, however, also varied, as did 
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those calculated with the diffusion rate-limited model. This variation 
argues against both the capacity-limited and the diffusion rate-limit­
ed models. In these models the parameters should not be influenced by 
concentration and volume. 
Both models, though providing good fits to the data, do not seem to be 
based on fully appropriate concepts of the absorption of insulin. A 
more realistic model of the absorption process might be obtained by 
combination of both concepts. In contrast with Binder (11) who 
suggested a diffusion rate-limited transport through the capillary 
pores, Hildebrandt et al (17) put forward the possibility of an active 
transport of polymeric insulin across capillary membranes in channels 
of fused vesicles. A combination of a bi-exponential model with the 
Michaelis-Menten model might be appropriate to describe this concept. 
It seems, however,that at this moment data proving one of the explana­
tory models for the absorption of subcutaneously injected insulin are 
still lacking. 
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CHAPTER IV 
THE VARIABILITY OF THE ABSORPTION OF SUBCUTANEOUSLY INJECTED INSULIN: 
EFFECT OF INJECTION TECHNIQUE AND RELATION WITH BRITTLENESS 
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Summary 
In this study insulin absorption rate and its variability were com-
pared between healthy persons (n=12), matched type 1 diabetics (n=12) 
and brittle type 1 diabetics (n=13) after subcutaneous injection with 
a standardized injection technique. In each individual 8 U of 1251-
labelled regular insulin were injected twice, between fat and muscle 
layers. Disappearance of radioactivity was measured during 8 hours. A 
difference in absorption rate could not be demonstrated between these 
three groups. Intraindividual variance was not larger in both diabetic 
groups than in the healthy persons, but a significantly larger inter-
individual variance was found in the diabetic groups. Injection with a 
less standardized technique, i.e. the skinfold technique each patient 
usually employed, did not alter mean absorption rate or its variabili-
ty. In a group of type 1 diabetics (n=27) the absorption after deep 
injection was compared with that after superficial injection, but no 
differences were found in absorption parameters, nor in a subgroup 
(n=10) in plasma free insulin and plasma glucose concentrations. We 
conclude that the variability in absorption between diabetic patients 
is larger than between healthy persons, but that mean absorption rate 
is the same and is not influenced by techique or depth of injection. 
Furthermore variable absorption of insulin is not the cause of 
brittleness in our group of brittle diabetics. 
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INTRODUCTION 
A large variability in absorption rate of subcutaneously injected 
insulin has been described (1,2). Many factors influence the absorp-
tion rate as, for example, exercise, smoking, temperature, but even 
under similar conditions a large intra- and interindividual variabili-
ty remains. After injection of regular 125i_insuiin tlie coefficient of 
variation of the T50, i.e. the time until 50% of the radioactivity has 
disappeared from the injection site, is 15% for the intra- and 30% for 
the interindividual variability (3). These coefficients of variation 
are 25% and 50%, respectively, after injection of intermediate-acting 
insulin (4). Plasma insulin concentrations after subcutaneous injec-
tion have been shown to vary to the same degree (5,6). Variation of 
the blood flow in the subcutaneous fat has been suggested as the cause 
of this variability (7,8,9), but it also seems possible that small 
changes in method of injection alter the absorption rate. The effect 
of alterations in injection technique, depth of injection and thick-
ness of the subcutaneous fat layer on the absorption rate of insulin 
and its variability have seldom been studied systematically, sometimes 
with controversial results. In this study we standardized the injec-
tion technique with syringe and needle, to allow injection at a repro-
ducible place: in the capillary plexus between fat and muscle layer. 
The absorption rate and its variability were measured in healthy vo-
lunteers and in patients with stable type 1 (insulin-dependent) dia-
betes. The influence of injection technique was studied by comparing a 
standardized injection method with the patient's own technique. To 
study the influence of depth of injection and thickness of the sub-
cutaneous fat layer on the absorption rate, insulin was injected in a 
large group of type 1 diabetics with varying fat thicknesses, once 
superficially at 3 mm from the skin surface and once between fat and 
muscle layers. 
As it has been suggested that defective (10) or erratic (11) absorp-
tion of subcutaneously injected insulin is a cause of brittleness of 
diabetes, we studied insulin absorption and its variability after 
standardized conventional injection in a group of brittle type 1 dia-
betic patients and compared the results with those in stable diabe-
tics. 
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METHODS 
Measurement of absorption rate. 
On the 2 days preceding the study the participants had taken Lugol's 
solution 3 times a day to prevent the accumulation of radioactive 
iodine in the thyroid. At 0830 h θ U of 125i_A
c
trapid HM (concentra­
tion 40 U/ml, specific radioactivity 3.0 uCi/ml; Novo Industri, 
Bagsvaerd, Denmark) were injected in the middle third of the upper 
leg. 
The amount of radioactivity at the injection site was measured imme­
diately after the injection and again every 30 minutes until the end 
of the study, using a Nal scintillation crystal with a diameter of 5 
cm, a collimator diameter of 7.5 cm and a distance to the skin of 2.5 
cm. The number of counts measured was expressed as percentage of the 
initial amount of counts and plotted against time. The disappearance 
of radioactivity was taken as a measure for the absorption of insulin 
according to Binder (3). The experiments were performed at a constant 
room temperature of 21 °C. The participants were not allowed to smoke 
or to drink coffee or tea. Between the measurements they were in a 
sitting position. 
Injection technique. 
Unless stated otherwise a standardized injection technique with a 1 ml 
syringe and a 0.5 χ 24 imi needle was used. The thickness of skin with 
subcutaneous fat on the middle third of the front of the upper leg was 
carefully measured, using ultrasound (Triscan, Biophysic Medical Ine) 
(12). The syringe with needle was placed in a holder allowing injec­
tion at a constant angle of 45° and determination, by means of a 
ruler, of the exact depth of insertion of the needle. To obtain the 
length necessary to inject the insulin between fat and muscle layers 
the thickness of skin with subcutaneous fat was multiplied with J2. 
The injections were given by the same investigator, alternately in 
left and right leg. 
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Subjects and protocols. 
The following groups were studied: 
1. Twelve healthy volunteers and 12 stable type 1 (insulin-dependent) 
diabetic patients matched for sex, age and weight, without diabetic 
complications or lipohypertrophy and not taking any medication, 
were studied twice. 
The healthy volunteers were kept fasting from 2300 h the day before 
until the end of the study 8 hours after the injection. In these 
subjects blood for measurement of plasma insulin and glucose was 
taken immediately before and every 30 minutes after the injection 
of 8 U of 125i-Actrapid HM. If a blood glucose concentration of 2.5 
mmol/l or less was measured they took a small amount of carbohy-
drate. Blood glucose concentrations after ingestion of carbohydrate 
were not used for calculations. 
Immediately after the injection of 8 U of labelled insulin the dia-
betic patients injected an adapted dose of their usual amount of 
insulin in the contralateral leg. They were allowed their usual 
meals. 
In Table I some characteristics of the healthy volunteers and the 
matched type 1 diabetic patients are given. None of the patients 
had clinical signs of retinopathy, nephropathy or neuropathy. They 
had only moderate levels of insulin antibodies. 
2. Eight out of the 12 diabetic patients subsequently injected them-
selves twice with 8 U of 125i-Actrapid HM, using their own injec-
tion technique and their own syringe and needle. All of them used 
the skinfold technique. The same protocol as in the first part of 
the study was followed. 
3. In 27 patients with type 1 diabetes without lipohypertrophy 8 U of 
125i_ACtrapid HM were injected twice, once superficially at a depth 
of 3 mm beneath the skin surface and on another day deep subcuta-
neously between fat and muscle layers. In 10 of them, each without 
endogenous secretion of insulin, plasma concentrations of free 
insulin and glucose were measured before and every 30 minutes after 
the injection during the 8 hours of the study. They were kept 
fasting from 2300 h the day before until the end of the study. If a 
plasma glucose concentration of 2.5 mmol/L or less was measured 
they had to eat an extra meal to prevent hypoglycaemic symptoms. 
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Table I 
Characteristics of healthy volunteers and two groups of type 1 diabetic 
patients participating in the study. 
sex (M:F) 
age (yr) 
length (cm) 
weight (kg) 
body mass index (kg/m2) 
ultrasonic thickness 
of subcutaneous fat | 
duration of ι 
insulin dose 
HbAi (%)* 
"Bo"(*)** 
ji abetes 
U/24hrs 
U/kg 
[mm) 
(yr) 
Healthy 
volunteer 
(n-12) 
6:6 
29.1+8. 
175.7+ 9. 
70.0+ 9. 
22.6 + 1. 
9.8+ 3. 
-
•s 
,7 
,6 
.6 
6 
.3 
Matched 
type 1 
diabetic 
patients 
(n-12) 
6:6 
31.2+ 9.1 
175.3+ 9.3 
70.4+ 9.2 
22.9+ 1.9 
8.4+ 3.1 
10.7+ 7.8 
54.5+21.6 
0.78+ 0.27 
9.7+ 1.3 
32.1+22.5 
Type 1 diabetic 
patients in whom 
depth of 
injection was 
varied (n=27) 
13:14 
30.8+10.2 
172.3+ 9.4 
71.0+ 7.2 
24.0+ 2.4 
9.9+ 4.3 
14.6+ 9.0 
52.2+16.7 
0.73+0.22 
9.6+ 1.8 
24.8+14.4 
Mean _+ SD, or number. 
* Normal range in our laboratory 5.5-7.9% 
** The mean value (+SD) of "Bo" was 8.6+0.9% in 20 normal subjects never 
treated with insulin. 
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Plasma glucose concentrations after this meal were not used for 
calculations. On the day before the study they only had used regu-
lar insulin 4 times a day, instead of their usual insulin regimen 
containing intermediate- or long-acting insulin preparations. Thus 
an influence of longer-acting insulins on measured plasma insulin 
concentrations was excluded. 
Clinical data of this group of patients, are given in the right 
column of Table I. Twenty-three patients did not have any sign of 
complications and did not take any medication. Only in 1 patient 
(autonomous) neuropathy was present. The urinary C-peptide concen-
trations in each of the ten patients in whom plasma concentrations 
of glucose and insulin were measured, were <0.08 pmol/ml, indicat-
ing the absence of endogenous insulin secretion. The patients in 
this group had moderate amounts of insulin antibodies. 
4. Insulin absorption was also studied in brittle diabetics. Thirteen 
patients were studied twice. Measurement of plasma insulin and glu-
cose concentrations was not performed. The results in this group of 
patients were compared with those in the (stable) diabetic 
patients. If they were on continuous subcutaneous, intraperitoneal 
or intravenous infusion of insulin, this treatment was continued 
during the study, with an adaptation of the pre-breakfast bolus 
dose of insulin. 
Brittle diabetes is defined by unpredictable and unexplained large 
fluctuations in plasma glucose during one day and from day to day, 
"leading to metabolic instability sufficient to cause disruption of 
the life-style or endanger the life of a patient" (13). Known 
causes of variability of plasma glucose, as large variation in 
diet, activity and insulin dose, inadequate insulin regimen, in-
fections, endocrine and other intercurrent diseases, were excluded. 
In Table II some clinical characteristics are given. All were C-
peptide negative and all except one practised very frequent self-
control of blood glucose levels and self-regulation. Seven of the 
patients had been referred to our hospital because of the brittle-
ness of their diabetes. Eight patients were not able to do their 
jobs because of the brittleness of their diabetes. 
All of the participants in these studies gave their informed consent. 
The hospital ethical committee approved of the protocols. 
Table II 
Characteristics of the brittle type 1 diabetic patients participating in the study. 
patient 
number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
sex 
(M,F) 
age 
(yr) 
17 
51 
26 
32 
33 
25 
47 
41 
26 
72 
24 
35 
40 
DM 
(yr) 
6 
22 
14 
10 
22 
19 
16 
12 
10 
43 
13 
8 
32 
duration 
brittleness 
(yr) 
(approximate) 
2 
8 
5 
4 
4 
4 
3 
3 
5 
16 
10 
8 
3 
insulin 
mode of 
therapy 
admini- U/24 
stration* 
CIVII 
CIPII 
CIPII 
CSI I 
SC 
CSI I 
CSII 
sc 
CSII 
sc 
CSII 
CSII 
CSII 
hrs 
36 
55 
80 
40 
34 
52 
40 
88 
62 
20 
29 
70 
40 
U/kg 
0.86 
0.81 
1.09 
0.50 
0.65 
0.80 
0.54 
1.10 
0.84 
0.39 
0.43 
0.89 
0.71 
HbAi 
(*) 
13.5 
9.5 
8.0 
8.3 
10.0 
11.6 
10.0 
12.6 
10.4 
14.6 
12.1 
8.6 
12.5 
A 
8.8 
54.5 
57.7 
unknown 
65.9 
51.0 
27.8 
22.2 
77.5 
9.0 
20.1 
45.0 
37.0 
d i abet i с 
complications 
_ 
+ 
+ b 
. 
+ a 
+ b 
+ c,e 
-
+ a,c,e 
+ 
+ с 
+ b,d 
a. non-proliferative retinopathy 
b. proliferative retinopathy 
с peripheral neuropathy 
d. proteinuria (/'2g/24h) 
e. cardiovascular complications 
(myocardial infarction and 
cardiac insufficiency with 
pacemaker implantation, respectively) 
*CIVII continuous intravenous insulin infusion 
CIPII continuous intraperitoneal insulin infusion 
CSII continuous subcutaneous insulin infusion 
SC subcutaneous insulin injections 
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Laboratory methods 
Plasma glucose was assessed inmediately after taking the blood samples 
by a Reflomat glucose meter (Boehringer Mannheim BV, Almere, The 
Netherlands) and was also measured with an autoanalyzer using the glu-
cose oxidase method. Plasma free and total insulin were measured 
according to the method of Nakagawa (14). After the blood sample was 
drawn it was centrifugated immediately at 3700 g during 5 minutes at 
21 °C. Part of the plasma was meant for measurement of total insulin 
and was frozen at -20 °C. An equal volume of polyethyleneglycol 
(250g/l) was added to the sample meant for measurement of free insulin 
in order to precipitate antibody-bound insulin. After renewed centri-
fugation, at 3700 g and 21 °C during 3 minutes, the supernatant was 
frozen at -20 "C. All samples were measured on the same day. The intra 
and inter assay coefficients of variation of free insulin are 5.6 and 
11.1%, respectively. Plasma and urinary C-peptide concentrations were 
measured as described earlier (15), without addition of polyethylene 
glycol. The intra- and interassay coefficients of variation of 
C-peptide are 5.3 and 9.9%, respectively. HbAi percentages were 
measured after an overnight incubation of the erythrocytes in 0.9% 
NaCl by the Quick-Sep-kit (16). 
In all of the diabetic patients the insulin binding capacity of the 
plasma was estimated as previously described (17) and expressed in 
the percentage of radioactive insulin bound after addition to insulin-
free patients plasma in the absence of unlabelled insulin ("BQ")· 
Statistical methods 
Results are given as mean +_ standard error of the mean (SEM), unless 
stated otherwise. 
Mean values of residual radioactivity, plasma (free) insulin, C-pep-
tide and glucose were calculated for every time point. In repeated ex-
periments only the first were used to calculate means. Means were com-
pared using Wilcoxon's signed rank test in paired samples and 
Wilcoxon's rank sum test in independent samples. 
Areas under the curve (AUCs) of insulin for every period of 0.5 h and 
for every cumulative interval from the injection up to a total period 
of 6 h (cumulative AUCs) were calculated in the healthy volunteers 
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for every curve, using the trapezoidal rule. Spearman's correlation 
coefficients were calculated between the residual radioactivity after 
every 0.5 h period (expressed in a percentage of the initial number of 
counts) and the corresponding cumulative AUC of insulin. The same cor-
relation coefficient was calculated for the correlation between the 
thickness of the subcutaneous fat and the T50 ° f the radioactivity at 
the injection site. 
The intraindividual and interindividual variation of the residual 
radioactivity at every time point was expressed in intraindividual 
and interindividual SDs, respectively. These SDs were compared 
between groups with the rank sum test and within groups with the 
signed rank test. The mean T50 of residual radioactivity was calcu-
lated for each group. Its intrasubject variance was expressed in the 
relative duplo SD and its intersubject variance in the coefficient of 
variation. Differences in T50 between groups were tested with one way 
analysis of variance. 
Comparisons between curves of decay of radioactivity and of increase 
in plasma free insulin after deep and superficial injection were made 
with a distribution-free analysis of variance (18). 
RESULTS 
1. Standardized injection technique in healthy volunteers and matched, 
type 1 diabetic patients (Fig 1, 2 and 3, table III). 
The mean decay of residual radioactivity in the healthy volunteers 
and the matched type 1 diabetic patients did not differ. Because 
the curves in the healthy volunteers and the matched type 1 dia-
betic patients overlap, only the results in the healthy volunteers 
are shown in Fig. 1. Table III gives the mean of residual radio-
activity in both groups. The mean T50 in the healthy volunteers was 
207+30 (SD) min and 224+73 min in the matched diabetics (NS). The 
intraindividual variance of this parameter was 17% and 12%, res-
pectively (NS). The interindividual variance was 14% and 33%, 
respectively (p=0.03). 
The intraindividual SDs of residual radioactivity measured at every 
time point varied in the healthy volunteers between 3.3 and 7.7% 
and were significantly (p<0.01) larger than in the matched dia-
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Fig. 1 Residual radioactivity at the injection site as percentage of 
the initial number of counts (mean + SE) after SC injection of 
8 U of 125i_iabelled human regular insulin in 12 healthy volun­
teers. Arrow indicates time of injection. 
betics (range between 2.2 and 6.6*). The interindividual SDs of 
residual radioactivity also measured at every time point were sig­
nificantly (pO.001) smaller in the healthy subjects (range between 
2.3 and 11.8%) than in the diabetics (range between 4.5 and 24.5%). 
The plasma concentrations of insulin, C-peptide and glucose in the 
healthy volunteers are shown in Fig 2. There was a significant 
(p<0.05) correlation between residual amount of radioactivity and 
cumulative AUC of plasma insulin (percents of total AUC) between 2 
and 6 h after injection. The correlation coefficients varied 
between 0.70 and 0.86. 
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Fig 2 Plasma insulin, C-peptide and glucose concentrations (mean +_ 
SE) after SC injection of 8 U of 125i-labelled human regular 
insulin in healthy volunteers. (Same experiment as Fig 1). 
Arrow indicates time of injection of insulin. Numbers in the 
curve indicate number of observations. 
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Table III 
Residual radioactivity at the site of injection (mean +_ SE), expressed 
as percentage of initial number of counts in 3 groups after injection 
of labelled insulin using a standardized, conventional injection tech-
nique. 
Time Healthy Stable type 1 Brittle type 1 
(h) volunteers diabetic patients diabetic 
(n=12) (matched with the healthy patients 
volunteers) (n=12) (n=13) 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
5 
5.5 
6 
6.5 
7 
7.5 
8 
100 
94.6 + 
86.7 + 
78.6 + 
70.6 + 
63.1 + 
54.2 + 
47.4 + 
41.3 + 
36.4 + 
31.0 + 
26.7 + 
22.6 + 
19.3 + 
16.6 + 
14.8 + 
13.6 + 
0.6 
1.0 
1.3 
1.5 
1.7 
1.8 
1.8 
2.0 
2.1 
2.0 
1.9 
1.9 
1.7 
1.6 
1.6 
1.6 
100 
94.9 + 0.7 
86.9 + 1.4 
79.2 + 2.1 
71.0 + 2.8 
62.8 + 3.0 
54.6 + 3.4 
49.1 + 4.0 
43.3 + 3.6 
37.3 + 3.5 
32.2 + 3.4 
28.0 + 3.2 
25.5 + 3.0 
23.2 + 3.0 
19.4 + 2.8 
19.3 + 2.6 
16.1 + 2.5 
100 
94.2 + 0.8 
86.5 + 1.3 
78.7 + 1.8 
70.8 + 2.2 
63.0 + 2.6 
56.1 + 2.9 
49.0 + 3.0 
43.3 + 3.1 
38.1 + 3.2 
33.2 + 3.2 
29.5 + 3.1 
25.2 + 3.0 
22.2 + 3.0 
19.1 + 2.8 
16.8 + 2.7 
14.8 + 2.5 
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Standardized injection technique compared with skinfold technique 
in type 1 diabetics (Fig 3). 
The differences in residual radioactivity after both injection 
techniques were not significant at any time point. Intraindividual 
SDs of radioactivity varied between 2.2 and 6.9% and interindivi­
dual SDs between 3.6 and 15.5% when patients used their own injec­
tion technique. These values were not significantly different from 
those when using the standardized technique (see above). The mean 
T50 of the radioactivity was 179+52 (SD) min. The intra- and inter-
individual variance of the T50 was 14% and 29%, respectively, which 
is not significantly different when compared with the standardized 
technique. 
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Fig 3 Residual radioactivity at the injection site as percentage of 
the initial number of counts (mean +_ SE) after SC injection of 
8 U of 125i-iabelled human regular insulin in type 1 diabetic 
patients using a standardized technique > t and their own 
(skinfold) technique 0 — 0 . Arrow indicates time of injection 
of insulin. 
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Deep and superficial injection compared in type 1 diabetics (Fig 4, 
Fig 5 a-b). 
The residual radioactivity after deep injection was significantly 
(p 0.05) lower at 7 and 8 h after injection. Total curves did not 
differ significantly. Because the mean values of free insulin 
before injection were significantly (p=0.02) different, each value 
of free insulin was corrected for its basal value. After deep 
injection a significantly higher (p<0.05) increase was found at 
0.25, 2, 2.5, 4, 4.5 and 5 h after injection. The total curves, 
however, did not differ significantly (p=0.08). Mean plasma glucose 
concentrations were never significantly different. A correlation 
between thickness of subcutaneous fat and T50 was neither found for 
deep nor for superficial injection. 
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Fig 4 Residual radioactivity at the injection site as percentage of 
the initial number of counts (mean jf SE) after deep >• · and 
superficial 0---0 injection of 8 U of IZSj-iabelled human re­
gular insulin in type 1 diabetic patients. Arrow indicates time 
of injection of insulin and asterix indicates 5% level of sig­
nificance between the curves. 
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Fig. 5 Increase of plasma free insulin concentrations and actual 
plasma glucose concentrations (mean +_ SE) after deep · — · and 
superficial о — о SC injection of 8 U of 125i_iabelled human 
regular insulin in type 1 diabetic patients. Arrow indicates 
time of injection of insulin and asterix indicates S% level of 
significance between the curves. 
Standardized injection technique in brittle diabetics compared with 
stable diabetics (Table III). 
The mean decrease in residual radioactivity in brittle diabetics 
was similar to that in the stable diabetics. The intra- and inter-
individual SDs of residual radioactivity ranged from 3.5 - 6.3 and 
from 5.3 - 23.0%, respectively. These parameters were not signifi­
cantly different from those in stable diabetics. The mean T50 of 
residual radioactivity was 217+80 min. The intra- and interindivi­
dual variance of the T50 was 14* and 39«, respectively, which is 
not significantly different from the results in the stable type 1 
diabetic patients. 
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DISCUSSION 
In this study some aspects of the variability of the absorption of 
subcutaneously injected neutral regular human insulin were investi-
gated. For this purpose a standardized injection technique was devel-
oped, which allowed deposition of insulin between fat and muscle 
layers. 
The absorption rate in the healthy volunteers expressed as T50, was 
slower than in similar studies with regular insulin. Binder (1) gives 
a mean T50 after subcutaneous injection in the femoral region of 
164+15 min, while we found 207+30 min. This difference was expected, 
because our subjects, in contrast with those in most earlier studies, 
were seated throughout the study. It has been shown that sitting pro-
longs the time of absorption in comparison with a supine position 
(19). A significant correlation was found between the residual radio-
activity at the injection site and the cumulative AUC of insulin for 
the same period, indicating that the method of external counting of 
radioactivity is valid. The variability of T50 was similar to that 
described in the literature, despite careful standardization of tech-
nique and depth of injection. When compared with the group of matched, 
stable, type 1 diabetic patients without complications, in whom the 
same injection technique was used, no differences in disappearance 
rate of radioactivity were found. The intraindividual variability of 
the absorption process, however, was smaller in the type 1 diabetics 
than in the healthy volunteers. The difference in this respect, though 
statistically significant, was not considered of clinical importance. 
Uncomplicated diabetes mellitus can be excluded as a cause of intra-
individual variability. 
The variability between individuals, however, is larger in type 1 dia-
betic patients than in healthy volunteers (p<0.001). The reason for 
this larger variability in diabetic patients without signs of peri-
pheral or autonomous neuropathy and without lipohypertrophy is not 
clear. It may be caused by a wider range in blood glucose concentra-
tions in the diabetics,, as it has been suggested that subcutaneous 
blood flow is influenced by blood glucose concentration. This in-
fluence on subcutaneous blood flow, however, has not been fully eluci-
dated (20,21). 
In 8 type 1 diabetics, the standardized injection technique was com-
pared with the skinfold technique they usually employed. The patients 
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used their own syringes, needles and their own technique. Despite 
these different methods the differences in absorption rate and its 
intra- and interindividual variability were not significant. The tech-
nique of subcutaneous injection of insulin obviously is not important. 
The use of different injection techniques has been reviewed by Binder 
et al (1). They found no differences between studies in which the in-
jection had been performed perpendicular to the skin surface with a 
needle length of 10 mm and studies in which insulin had been injected 
in a skinfold at an AS" angle and with a needle length of 25 mm. Heine 
et al (22) systematically compared both techniques and did not find 
any difference in plasma insulin and glucose concentrations. Our 
results are in accordance with these findings. 
The literature concerning the influence of depth of injection has been 
conflicting. Ktflendorf et al (9) did not find any difference in ab-
sorption rate whether insulin was injected at 5, 10 or 15 mm beneath 
the skin surface, while Hildebrandt et al (23) found a faster absorp-
tion after injection at a depth of 12 mm than at a depth of 3 inn from 
the skin surface. In the only other study (24) that compared super-
ficial injection with injection at an individualized depth between fat 
and muscle layers, a significant acceleration of absorption after deep 
injection was found. We studied the influence of depth of injection in 
a large group of 27 stable diabetic patients. Insulin once was inject-
ed very superficially, only just beneath the skin, and once between 
fat and muscle layer using the standardized injection technique with 
an individualized needle length. The deep level of injection was care-
fully determined in every individual by an ultrasound technique, which 
has not been done in other studies. In a subgroup of these patients 
plasma insulin and glucose concentrations were measured. The increase 
in plasma free insulin was significantly higher in several time inter-
vals after deep injection, but the curves in total were not signifi-
cantly different. As we neither found differences in decay of radio-
activity and decrease of plasma glucose concentrations, we conclude 
that the difference between deep and superficial injection is without 
clinical significance. 
A correlation between thickness of fat layer and absorption, rate after 
deep subcutaneous injection was, in contrast with earlier reports (9), 
not found. This lack of correlation might have been caused by our 
method of deep injection of insulin beneath the fat layer instead of 
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in the subcutaneous fat. 
Several explanations have been proposed for the syndrome of brittle 
diabetes (25,26). Among these, defective and variable subcutaneous ab­
sorption of insulin have been described in brittle patients (10,11). 
The results in our patients, however, do not indicate absorption 
problems, as neither the absorption rate nor its variability did show 
any difference in comparison with stable diabetic patients. In a 
recent editorial (25) it has been stated that brittleness of diabetes 
often is caused by behavorial problems, rather than by absorption 
problems. Systematic approaches (27,28,29) to identify the cause of 
brittleness have shown psychological factors to be very frequent. 
We conclude that the intraindividual variability of the absorption 
rate of subcutaneously injected insulin is not caused by the diabetic 
state itself, nor by technique or depth of injection or thickness of 
the subcutaneous fat. The large interindividual variability in the 
diabetic groups might be caused by metabolic factors causing variation 
in subcutaneous blood flow. The absorption of insulin and its varia­
bility, moreover, are not different in brittle diabetic patients and 
are therefore apparently not the cause of the brittleness. 
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CHAPTER V 
INSULIN ANTIBODIES DO NOT INFLUENCE THE ABSORPTION RATE OF 
SUBCUTANEOUSLY INJECTED INSULIN 
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Summary 
The influence of insulin-antibodies on absorption rate and plasma free 
insulin concentrations after subcutaneous injection of insulin was 
studied in two groups of insulin-treated diabetic patients, one 
without insulin antibodies (n=9) and a second with high plasma concen-
trations of antibodies (n=14). Except for antibody concentration there 
were no differences in clinical variables. During 8 hours after the 
injection of 12 U of lodinated neutral human insulin residual radio-
activity at the injection site, plasma glucose and free and total 
insulin were measured. 
Significant differences in absorption rate of insulin were not found 
between the groups. Plasma glucose (basal value 16.8+4.4 SD vs 
16.1+4.2 mmol/l) and free insulin (basal value 8.3+1.4 vs 11.4+2.3 
mU/l, maximum after 90 m m 36.9+19.5 vs 30.5+18.7) were never signi-
ficantly different between the groups, nor were areas under the curve 
of free insulin. In the high antibody group a small increase in bound 
insulin was obtained. 
So, despite a maximum difference in antibody concentration, only minor 
differences were found in the measured variables. Insulin antibodies, 
therefore, are of no clinical importance. 
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INTRODUCTION 
Since insulin antibodies were demonstrated by Berson and Yalow (1), 
their presence has been held responsible for several clinically im-
portant phenomena in insulin-treated diabetic patients. Very high con-
centrations of insulin antibodies can cause insulin resistance (2). 
Lower levels of antibodies, as seen since chromatographically purified 
insulins are in general use, may also have clinical effects. A favour-
able, stabilizing influence of circulating insulin antibodies on the 
metabolic regulation of diabetic patients has been suggested (3,4), 
but negative effects have also been reported, such as unexpected (51 
and prolonged (6,7) hypoglycaeima and a shorter remission period in 
newly diagnosed type 1 diabetes (8). 
Conflicting reports have been published on the influence of insulin 
antibodies on the plasma free insulin concentration obtained after 
subcutaneous (SC) or intravenous injection or infusion of insulin 
(9,10,11,12). 
A possible effect of insulin antibodies on plasma free insulin levels 
might be the association of a part of the absorbed insulin to anti-
bodies. This would cause a smaller and delayed insulin peak. A delay 
in absorption of injected insulin by insulin antibodies has also been 
suggested in the literature (9,13). However, no direct studies of the 
influence of insulin antibodies on the absorption of insulin have as 
yet been reported. 
The aim of our study was to investigate whether the presence of in-
sulin antibodies has an effect on the rate of absorption of subcuta-
neously injected insulin and on the resulting plasma free insulin 
levels. In order to obtain a clear answer, we recruited two groups of 
diabetic patients with a maximal difference in plasma insulin antibody 
concentration. 
PATIENTS AND METHODS 
Patients 
Plasma insulin binding capacity was measured in 200 diabetic patients 
attending our out-patient clinic. None of them had an excessive need 
of subcutaneously injected insulin, suggesting the syndrome of subcu-
taneous insulin resistance. 
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Entry criteria were: duration of insulin therapy more than 1 year; no 
lipohypertrophy at the injection site; no medication except insulin. 
Patients with a plasma binding capacity ('Bo') less than the mean + 
2SD of the binding obtained in 10 healthy volunteers, formed the first 
group ('undetectable insulin antibodies'). Patients with a plasma 
binding capacity in the presence of 1000 pg non-labelled insulin 
('BlOOO') of more than 25 % formed the second group ('high levels of 
insulin antibodies'). 
All of the patients gave their informed consent. The study protocol 
was approved by the hospital ethical committee. 
The first group consisted of 9 patients of whom б had type 1 (insulin-
dependent) and 2 had type 2 (non-insulm-dependent) diabetes mellitus; 
one patient had diabetes secondary to chrome pancreatitis. Two 
patients had proliferative retinopathy and proteinuria (less than 2 
g/24-h) in these patients. The second group contained 14 diabetic 
patients with high concentrations of insulin antibodies. Thirteen had 
type 1 and one had type 2 diabetes. In this group one patient had pro­
liferative retinopathy. None of the patients in either group had 
clinical signs of neuropathy. All of them were within 20 % of their 
ideal body weight according to the tables of the Metropolitan Life 
Insurance Company, except for 1 elderly lady in the second group who 
was 35 % above her ideal body weight. A 24-h urine sample for measure­
ment of C-peptide concentration (14) was obtained from all patients to 
assess endogenous insulin secretion. An excretion of more than 0.10 
pmol/24-h was considered to represent a significant endogenous insulin 
production. Clinical characteristics are summarized in Table I. 
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Table I 
Clinical data of patients participating in the study 
Undetectable plasma 
insulin antibodies 
High plasma 
insulin antibodies 
N 
Sex (M:F) 
Age (yr) 
Type of diabetes (1/2/secondary) 
Duration of diabetes (yr) 
Duration of insulin therapy (yr) 12.6+13.3 (1-40) 
9 
4 : 5 
39.9+12.3 (26-58) 
6/2/1 
13.6+12.9 (1-40) 
Ideal body weight {%) 
HbAl (%)* 
Insulin dose (U/kg) 
Species of injected insulin 
(human/pork/mixed beef:pork) 
'Bo' (%)** 
'BlOOO' (*)** 
101.3+8.6 (89-112) 
9.9+0.9 (8.0-10.8) 
0.83+0.24 (0.38-1.31) 
2/5/2 
8.8+1.0 (7.0-10.8) 
7.9+0.7 (7.2+9.4) 
14 
6 : 8 
37.4+16.4 (19-69) 
13/1/0 
13.2+10.0 (1-41) 
12.9+10.1 (1-41) 
108.7+11.9 (89-13) 
9.9+1.5 (7.7+12.4) 
0.72+0.29 (0.45-1.26) 
0/8/6 
64.2+12.0 (42.6+83.0) 
37.3+19.8 (21.0+81.2) 
Mean +_ SD (range), or number 
* Normal range in our laboratory 5.5-7.9% 
**In 20 normal subjects never treated with insulin, mean values (+SD) for 
'BQ' and 'Biooo' were 8.6 + 0.9 and 8.4 + 0.9 %, respectively. 
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Study protocol 
The patients in both groups followed the same protocol. Twelve units 
of 1251 neutral human soluble insulin (specific radioactivity 3.0 
mCi/1; Novo Industri, Bagsvaerd, Denmark) were injected SC in the 
middle third of the upper leg at 0900 n. The injections were performed 
in a standard way. The thickness of skin and subcutaneous fat layer 
was measured by echography to allow the deposition of the injected 
insulin in the interface between fat and muscle layer (15). 
The radioactivity at the injection site was measured immediately after 
injection and subsequently every 30 min for θ h, using a Nal-scin-
tillation crystal (diameter 50 mm; distance to skin 25 mm; collimator 
diameter 75 mm). The disappearance of radioactivity was used as a 
measure for insulin absorption, according to the method of Binder 
(16). The number of counts measured is expressed as percentage of the 
initial number and plotted against time. 
Blood for measurement or blood glucose and plasma free and total in­
sulin concentration was taken immediately before the injection of 
125i_label led insulin and every 15 min thereafter during the first 2 h 
and every 30 min for a further 6 h. 
The patients took Lugol's solution three times a day on the 2 days 
preceding the study to prevent accumulation of 125i in the thyroid. 
The day before the study they were treated only with short-acting 
insulin, 4 times a day. The last injection was given at 2300 h. To 
be sure that an increase of insulin levels during the 8 h of the study 
was caused by the exogenous insulin only, patients were kept fasting. 
If a blood glucose level of 3.0 mmol/l or less was reached before the 
end of the study, the patients were permitted to eat. The values for 
glucose and insulin obtained after eating were not used for calcula­
tions. During the study smoking was not permitted and the patients 
remained seated to exclude the influence of exercise and change of 
posture on the absorption rate of insulin. 
Laboratory Methods 
The estimation of insulin binding capacity was performed by first dis­
sociating insulin and insulin antibodies at low pH. Insulin was then 
absorbed onto dextran-coated charcoal (17), after which 125i-insulin 
(30 pg per 25 ul patients plasma) was added with and without 1000 pg 
of unlabel led insulin. After incubation for 3 days bound insulin was 
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precipitated by an equal amount of polyethyleneglycol (PEG) 250 g/1 at 
4 °C. Pellet radioactivity was counted and the amount of 125i-iabelled 
insulin bound to antibodies was expressed as percentage of the total 
amount of radioactive insulin added previously. The binding capacity 
of the plasma in the absence of unlabelled insulin was called 'BQ' and 
that in the presence of 1000 pg unlabelled insulin 'Вюоо'· 
Blood glucose was measured immediately by a Reflomat glucose meter 
(Boehringer Mannheim BV, Almere, The Netherlands) and later plasma 
glucose was measured by an autoanalyzer, glucose oxidase method. 
Plasma free and total insulin concentrations were determined by the 
method of Nakagawa (18). Immediately after sampling, the blood was 
centrifugated at 3700g for 5 min at 21° C. The plasma was divided into 
2 equal portions: one was frozen at -20° С and used to measure total 
(free plus bound) insulin levels. In the other sample antibody-bound 
insulin was precipitated immediately by addition of polyethyleneglycol 
250 g/1. After 3 min of further centrifugation at 3700g (21 °C) the 
supernatant was frozen at -20 °C. The intra and interassay coeffi­
cients of variation of the insulin assay in our laboratory are 5.6 and 
11.1 %, respectively. Measurement of free and total insulin concentra­
tions was performed at the same time in all samples. The amount of 
bound insulin is obtained by subtracting free insulin from total 
insulin concentrations. C-peptide in 24-h urine samples was measured 
with a modification of our previously described radioimmunoassay (14). 
Statistical Methods 
Unless stated otherwise results are given as mean +_ SE. Mean values of 
residual radioactivity, plasma glucose and free insulin concentrations 
in both groups were calculated for every time point and compared using 
Wilcoxon's rank sum test. Total curves of residual radioactivity and 
free insulin were compared using a distribution-free analysis of 
variance (19). 
Areas under the curve (AUCs) of free insulin for every 30-min period 
and for the total 8-h period were calculated for each patient, by the 
trapezoidal rule. Spearman's rank correlation coefficient was cal­
culated for 'BQ' with total insulin levels, and for percentage resi­
dual radioactivity with cumulative AUC of free insulin for the same 
period. 
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Since total and bound insulin levels in the high antibody group did 
not satisfy the criteria of normal distribution, the median with 
interquartile range was calculated. Wilcoxon's signed rank test was 
used to assess the significance of the increase in total and bound 
(total minus free) insulin concentrations. 
RESULTS 
a. Absorption of insulin 
No significant differences were found in percent residual SC radio-
activity between the high and undetectable insulin antibody groups 
(Fig 1). 
Residual radioactivity (°/o ) 
Timefh ) 
Fig 1 Residual radioactivity at the injection site as percentage of 
the initial number of counts (mean +_ SE) after SC injection of 
12 U of 125i_labelled neutral soluble insulin in diabetic 
patients with undetectable (o——o) and high ( · — · ) insulin 
antibody concentrations. 
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b. Plasma glucose 
Basal plasma glucose was 16.8 ±_ 4.4 mmol/1 (+_ SE) in the antibody-
negative group and 16.1 ^ 4 . 2 in the high-antibody group (NS). 
In seven patients (four in the antibody-negative group and three in 
the high-antibody group) a blood glucose level of 3.0 mnol/l or less, 
necessitating them to eat, was reached before the end of the study. In 
both groups the first patient had a hypoglycaemic reaction 270 m m 
after injection. In Fig 2 the decrease in the blood glucose level 
(mean _+ SE) is given for both groups until the time point when the 
first hypoglycaemic reaction occurred. No significant differences were 
found between the groups in blood glucose concentrations (up to the 
point where the first patient became hypoglycaemic)(Fig 2). 
Glucose(mmol/l ) 
20-
16 
12-
"1 Γ-
4 5 
Time (h ) 
Fig 2 Plasma glucose concentrations (mean + SE) after SC injection of 
12 U of neutral soluble insulin in diabetic patients with 
undetectable (o——o) and high (•—·) insulin antibody 
concentrations. 
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с. Plasma free insulin 
Basal plasma free insulin was 8.3 +_ 1.4 mU/1 in the antibody-negative 
group and 11.4 + 2.3 in the high-antibody group (NS). After leaving 
out patients with residual insulin secretion these values were 9.0 +_ 
1.8 and 11.7 + 2.6 (NS). 
After the injection a large intenndividual variation in increase in 
plasma free insulin levels was found in the patients of both groups. 
No significant differences between the 2 groups were found in free 
insulin concentrations over the course of the study (Fig 3), nor in 
AUC of free insulin or cumulative AUC (Table II). 
There was a significant (p<0.01) correlation between SC residual 
radioactivity and cumulative AUC of free insulin (expressed in 
mU.l-lh) in the same time period from 2 h after injection onwards in 
the antibody-negative group and from 2.5 h in the high-antibody 
group. 
Free insulin (pU/ml) 
50 
4 0 -
30 -
20 
10 
г 
8 
Time (h) 
Fig 3 Plasma free insulin concentrations (mean +_ SE) in diabetic 
patients with undetectable ( о — o ) and with high (•—·) in­
sulin antibody concentrations after SC injection of 12 U of 
neutral soluble insulin. 
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Table II 
Area under the plasma free insulin concentration curve (AUC) after SC 
injection of 12 U of neutral soluble insulin in patients with 
undetectable and high insulin antibody levels. 
Undetectable plasma High plasma insulin 
insulin antibodies (n=9) antibodies (n=14) 
total AUC (mU.l-lh) 191.4 ± 69.2 170.8 ± 98.6 
cumulative AUC 1 h 22.4 ± 10.0 21.1 * 15.5 
(mU.l-lh) 2 h 57.6 t 26.5 51.0 ± 32.0 
3 h 92.1 ± 39.7 79.9 ± 44.9 
Mean + SD 
The differences between groups are not statistically significant. 
Plasma total and bound insulin 
In the antibody-negative group the values for free and total insulin 
were identical (basal concentrations of free insulin 8.3+1.4 mU/1 and 
of total insulin 9.9+2.4). In the high-antibody group a large varia-
tion in individual total insulin levels was found, with basal concen-
trations ranging from 84 to 1448 mU/1. Basal total insulin concentra-
tion correlated with B Q (r=0.54; p O . 0 5 ) . 
In the period from 45 to 390 m m after injection a small, but signifi-
cant (p<0.05) increase in plasma bound insulin levels occurred in com-
parison to the basal concentrations (Fig. 4 ) . The fall of residual 
radioactivity and AUC of bound insulin did not correlate significant-
ly. 
101 
Δ bound insulin (mU/l 
2 5 0
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Fig 4 Change in plasma bound (total minus free) insulin concentra­
tions (median + interquartile range) after SC injection of 12 U 
of neutral soluble insulin in diabetic patients with high in­
sulin antibody concentrations. Level of significance (*p<0.05) 
calculated in comparison with the basal value before injection. 
DISCUSSION 
In some studies (9,10,11,12) lower plasma free insulin concentrations 
were found after subcutaneous injection of insulin in patients with 
insulin antibodies than in patients without. This finding can be ex­
plained by immediate binding of insulin by circulating antibodies in 
the blood or by an impaired absorption of insulin as suggested by some 
authors (9,13). Local binding of insulin by antibodies in the SC 
tissue might be a cause of such a delayed absorption. As insulin anti-
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bodies are of the IgG-class and as it is known tnat IgG-immunoglobu-
lins diffuse freely into the interstitial space (20), binding of in-
sulin by antibodies in the extravascular space seems a real possibili-
ty. Subcutaneous complexes of insulin and antibodies would probably be 
absorbed into the circulation more slowly than unbound insulin. 
We recruited a group of diabetic patients without insulin antibodies 
and another with high antibody concentration. The difference in bind-
ing capacity between the two groups was confirmed by the difference in 
total insulin levels: in the antibody-negative group the values for 
total and free plasma insulin were identical. In the high-antibody 
group, however, the concentrations of total insulin in every patient 
were higher than those of free insulin. In this group a significant 
correlation was found between 'BQ' and basal total insulin concentra-
tions. 
Differences in absorption rate of insulin were not found between both 
study groups. The presence of insulin antibodies, even in the high 
concentrations of the second group, apparently does not influence the 
absorption rate of subcutaneously injected insulin. 
Since the last injection of short-acting insulin had been administered 
10 hours before, basal blood glucose levels were rather high. If 
insulin antibodies are of any importance, one would expect consider-
ably lower basal plasma glucose levels in the high-antibody group at 
this time, due to dissociation of bound insulin from the antibodies. 
There was, however, no significant difference between the two groups 
in this respect. Francis et al. (9) found significantly lower blood 
glucose concentrations in a small group of C-peptide negative patients 
with moderate antibody levels than in a similar group with low anti-
body levels. However, more patients in the moderate antibody group had 
received a longer-acting insulin preparation the evening before than 
in the low antibody group. Vaughan et al. (21) also found lower blood 
glucose levels after discontinuing an intravenous infusion of insulin 
in patients with antibodies than in patients without. Comparison with 
our results is difficult, because intravenous infusion of insulin over 
24-h might cause a much higher binding of insulin by antibodies (and a 
delayed hypoglycaemic effect) than after SC injections. Because of the 
relatively slow absorption of the injected insulin, plasma glucose 
concentration decreased gradually towards the end of the study. The 
mean rate of decrease was approximately 2 mmol/1 per hour in both 
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groups. 
Plasma free insulin concentrations in both groups increased to the 
same degree. Differences in free insulin concentration between tne 
groups were never significant. 
The AUC of free insulin also was not significantly different at any 
moment between the 2 groups. Despite this absence of differences in 
free insulin, a significant increase in bound insulin as compared to 
the basal value occurred in the high antibody group. As bound insulin 
has a longer half-life than unbound, binding of only small amounts of 
insulin might cause a significant increase in bound insulin. After SC 
injection of human insulin in a group of patients with low and one 
with moderate antibody concentration, Francis et al. (9) found a sig-
nificantly higher concentration of free insulin in the first group 
only at one time point. Differences in other variables, especially 
after injection of bovine insulin were also found (AUC of free 
insulin, postprandial rise in blood glucose). It was, therefore, con-
cluded that the presence of antibodies blunts the onset of action of 
regular insulin. Lower plasma free insulin concentrations, higher in-
crease in postprandial glucose concentration (11) and differences in 
insulin pharmacokinetics (12) in patients with high antibody concen-
trations were also found by others. Another group of investigators 
(10) only found a minor influence of insulin antibodies on insulin 
kinetics, as we did. Thus, the conclusions of several recent studies 
are conflicting. Part of the explanation for these different findings 
might be the definition of the groups in the respective studies. More-
over, methods of measurement of insulin antibody concentrations are 
not always comparable in these studies. An extra argument for the ab-
sence of a clinically important influence of insulin antibodies in our 
study is that no difference in plasma glucose concentration was found 
between the 2 groups. This is the more significant because in the 
high-antibody group the patients with the highest antibody concentra-
tions from our out-patient clinic participated. In a prospective study 
(22) in newly diagnosed diabetic children who were treated during 1 
year, either with purified porcine or with partially purified bovine/ 
porcine insulin, a large difference in insulin antibody concentration 
was found. No differences in clinical parameters (insulin dose, C-
peptide and metabolic control, as judged by HbAi levels, fasting glu-
cose concentrations and reported episodes of nocturia and hypoglyc-
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aerina) were found, indicating the absence of clinical effects of 
insulin antibodies. 
Thus, an influence of the presence of high amounts of insulin anti­
bodies on the absorption rate of SC injected insulin was not found. 
Although some insulin was bound to insulin antibodies in the high-
antibody group, no significant difference in plasma free insulin and 
glucose concentrations was found, de conclude that insulin antibodies 
are of no clinical importance. 
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CHAPTER VI 
SUBCUTANEOUS INJECTION WITH AN INSULIN PEN. 
INSULIN ABSORPTION AND PLASMA CONCENTRATIONS OF GLUCOSE AND FREE 
INSULIN 
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Summary 
The insulin pen usually is employed in a basal-prandial injection 
regimen in order to obtain more physiological insulin concentrations 
than with a conventional regimen, and thereby to achieve normoglyc-
emia. 
In 6 type 1 diabetic patients treated with such a regimen, plasma con-
centrations of free insulin and glucose were measured during 24 
hours. Clear insulin peaks were obtained after a mean of 1 hour after 
injection of regular insulin and stable, lower, insulin levels were 
found during the night. Between the peaks the basal level of free 
insulin was not reached. Plasma glucose concentrations showed few 
fluctuations. 
In addition, in 10 healthy volunteers the absorption rate of insulin 
was studied after subcutaneous injection, twice with a standardized 
conventional technique and twice with a pen. During 8 hours after the 
injection of 125i-Actrapid residual radioactivity at the injection 
site and plasma concentrations of insulin and glucose were measured. 
No significant differences in these parameters were found, except for 
the insulin concentration 60 minutes after injection, which was higher 
after pen injection (p<0.05). The variability of the parameters was 
slightly larger after pen injection (p<0.02). 
We conclude that a basal-prandial injection regimen can cause stable 
glucose levels but only at the expense of a considerable hyperinsulm-
emia and that injection with an insulin pen, compared with 
conventional injection, does not cause important differences in 
absorption rate and plasma concentrations of insulin and glucose. 
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INTRODUCTION 
The insulin pen is a new device to facilitate the injection of insulin 
(1). Such a pen is usually employed for a basal-prandial injection 
regimen (2). In this regimen the patients inject intermediate-acting 
insulin at bedtime to supply a basal amount of insulin during the 
night, while short-acting (regular) insulin is injected before each 
main meal to prevent a rise in blood glucose after the meal. The aim 
of this regimen is to imitate plasma insulin concentrations in healthy 
man and thereby to achieve normoglycemia. Little is known, however, 
about the actual insulin concentrations with this regimen. 
Injection with an insulin pen, moreover, differs in some respects from 
injection with a conventional syringe and needle and therefore might 
cause differences in insulin absorption. First, the injection is given 
perpendicular to the skin surface using a short needle with a fixed 
length of 12.5 mm. In contrast with the technique commonly used in The 
Netherlands, a skinfold to allow deposition of the insulin between fat 
and muscle layers is not lifted. The insulin, therefore, is not in-
jected deep subcutaneously, but mostly will be injected more super-
ficially in the fat layer. Secondly, the insulin is delivered as a 
multitude of very reproducible (1) small doses of 2 U. This good 
reproducibility could mean more reproducible insulin and glucose con-
centrations than with the conventional technique, as it is well known 
that in using the latter technique large errors in dosage are made 
(3), even by experienced diabetic patients. Thirdly, as administration 
of a certain amount of insulin in a multitude of small doses causes a 
faster absorption rate than administration in one large dose (4), 
higher plasma insulin and lower plasma glucose concentrations might 
arise after injection with an insulin pen. 
We, therefore, decided to study the following questions. First, how do 
plasma free insulin concentrations develop after insulin injection 
with an insulin pen using the described regimen. Secondly, are there 
any differences in absorption rate, plasma insulin and glucose concen-
tration (and their reproducibility) after injection with an insulin 
pen as compared to conventional injection? 
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MATERIALS AND METHODS 
Study protocol 
1. Six patients with C-peptide negative type 1 (insulin-dependent) 
diabetes treated with a basal-prandial injection regimen, were 
hospitalized for 36 hours. Time and dose of insulin injections and 
diet were not changed. An insulin pen (NovoPenR, Novo Industri, 
Bagsvaerd, Denmark) was used for the injection of short-acting insulin 
(Actrapid HM PenfillR, 100 U/ml ) in the abdomen, 30 minutes before 
the 3 main meals. At 11.00 p.m. intermediate-acting insulin (Monotard 
HMR, 40 U/ml) was injected in the upper leg using the skinfold 
technique with a conventional 1 ml syringe and 0.5x24 rrni needle, 
because at the time of the study the Penfill vials of 
intermediate-acting insulin for the insulin pen were not yet available 
in The Netherlands. 
A 24-hour profile of plasma glucose, free and total insulin was 
measured. Starting at 7.30 a.m. blood was taken every hour with addi-
tional samples taken 30 minutes after the injection of short-acting 
insulin. During the night blood samples were taken once every 2 hours. 
2. The absorption studies were done in ten healthy volunteers. Each of 
them was studied on 4 separate days. On the 2 days preceding the study 
they took Lugol's solution 3 times a day to prevent accumulation of 
radioactive iodine in the thyroid. At 9.00 a.m. 8 U of ^¡.Actrapid 
HM1* (concentration 100 U/ml, specific radioactivity 3.0 Ci/ml; Novo 
Industri, Bagsvaerd, Denmark) was administered subcutaneously. The 
volunteers were kept fasting from 11.00 p.m. the day before until 8 
hours after the injection or until a plasma glucose concentration of 
2.5 mmol/L or less was measured previously. If that occurred or if 
hypoglycemic symptoms developed 1 or 2 biscuits (each containing 4 
grams of carbohydrate) had to be taken. 
On the first 2 days the injection was given by a standardized conven-
tional technique using a 1 ml syringe and a 0.5x24 mm needle. After 
measurement of the thickness of skin and subcutaneous fat using the 
Holtain Skinfold Caliper (Holtain Ltd, Croswell, Crymmych, Pembs, UK) 
the needle was inserted obliquely (45 °) at an individualized depth, 
aiming at injection of the insulin between fat and muscle layer. On 
the other 2 days the injection was given with the insulin pen perpen-
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dicular to the skin. In volunteers with a fat layer of less than 20 mm 
the injection was given on the top of a broad skinfold. The injections 
were always given in the middle 1/3 part of the front of the upper 
leg. During the study smoking was not permitted and the patients 
remained seated to exclude the influence of exercise and change of 
posture on the absorption rate of insulin. The radioactivity at the 
injection site was measured immediately after injection and subse-
quently every 30 minutes thereafter, using a Nal scintillation crystal 
(diameter: 5 cm; distance to skin: 2.5 cm; collimator diameter: 8 cm) 
during the 8 hours of the study. The disappearance of radioactivity 
was used as a measure for insulin absorption, according to Binder 
(5). The number of counts measured was expressed as percentage of the 
initial number and plotted against time, dith a mathematical formula 
for a 2-compartment system an experimental curve was fitted using the 
computer program NLIN (SAS Institute Ine, Cary, N.C.). In the fits all 
data received a weighting factor 1. A formula for such a 2-compartment 
model was chosen, because it was suggested in the literature (6) that 
insulin after subcutaneous injection in a first compartment diffuses 
to a second compartment where absorption into the blood takes place. 
In both compartments a minor degree of subcutaneous degradation might 
occur. The formula used was: 
100.(KSp.e-(Kd+Kl2)t - Ki2.e-(Kd+Ksp)t) 
Y(t) = 
Ksp - Ki2 
In this formula Y(t) is the mathematical function that fits the ob-
servations Y (residual radioactivity at the injection site as percen-
tage of initial radioactivity) as function of time. K12» Ksp and 
Kd are rateconstants for the transport of insulin from the first to 
the second subcutaneous compartment, for the transport from subcuta-
neous tissue to the blood and for subcutaneous degradation taking 
place in both compartments. The rate constants are expressed as per-
centage per minute. 
The absorption rate of insulin, the plasma free insulin, C-peptide and 
glucose concentrations resulting from the 2 injection techniques were 
compared, as were the reproducibilities of the given parameters for 
either technique. 
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All of the patients and volunteers gave their informed consent. The 
protocol was approved by the hospital ethical committee. 
Patients and volunteers 
Clinical data concerning the patients and healthy volunteers are given 
in Table I. 
The patients participating in the first part of the study had to meet 
the following criteria to enter the study: no endogenous insulin se-
cretion (defined as C-peptide concentration in a 24-hour urine samóle 
<0.06 pmol/ml), low concentrations of insulin antibodies (defined as 
insulin binding capacity (Bg) <15%), no 1ipohypertrophy at the in-
jection site, no obesity and no medication except insulin. None of the 
patients had clinical signs of sensory, motor and autonomous neuropa-
thy. Two of them had nephropathy (in these patients a proteinuria of 
less than 2 grams per 24 hours), in one of these patients in combina-
tion with proliferative and in the other with non-proliferative reti-
nopathy. 
Laboratory methods 
C-peptide concentrations in blood and urine were measured by radio-
immunoassay (7). Insulin binding capacity (BQ) was assessed as pre-
viously described (8). Blood glucose was estimated using a ReflomatR 
glucose analyzer (Boehringer Mannheim BV, Almere, The Netherlands), 
immediately after drawing the blood. For the exact measurement an 
autoanalyzer, using the glucose oxidase method was used. Plasma free 
and total insulin concentrations were measured using the method of 
Nakagawa (9). For this purpose the blood was centrifuged, immediately 
after sampling, at 3700 g during 5 minutes. A portion of the plasma 
meant for measurement of the total insulin concentration was frozen at 
-20 °C, while in the portion meant for measurement of the free insulin 
concentration the antibody-bound insulin was instantaneously pre-
cipitated by addition of 25% polyethyleneglycol. This portion was cen-
trifuged again at 3700 g during 3 minutes whereupon the supernatant 
was frozen at -20 °C. Concentrations of free (and total) insulin were 
measured in all samples on the same day. 
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Table I 
Clinical characteristics of 
a. type I diabetic patients employing the basal-prandial injection 
regimen (n=6). 
b. healthy volunteers participating in the absorption study (n=10). 
a. Type I diabetic b. Healthy 
patients (n=6) volunteers (n=10) 
3 : 3 sex (M:F) 4 : 6 
38.0 + 13.3 age (yr) 25.7 + 4.8 
171.7+6.2 length (cm) 173.3+4.8 
68.3+11.4 weight (kg) 64.5+11.2 
23.1 + 2.4 body mass index (kg/m2) 22.4 + 2.6 
18.3 + 4.6 skinfold (mm) 20.0 + 8.7 
19.0 +_ 13.1 duration of diabetes (yr) 
insulin dose: 
48.3 + 20.8 (U/24 hrs) 
0.71+0.30 (U/kg) 
10.5 + 0.6 HbAl [%)* 
Values expressed as mean _+ SD. 
*Normal range in our laboratory: 5.5-7.9% 
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Statistical methods 
Results are given as mean + standard error of the mean (SEM) unless 
stated otherwise. 
Mean values of residual radioactivity, plasma free insulin, C-peptide 
and glucose concentrations were calculated for every time point and 
compared using Wilcoxon's signed rank test. 
Experimental curves for the disappearance of radioactivity were cal­
culated individually with the formula given above. The calculated rate 
constants were compared using Wilcoxon's signed rank test. Areas under 
the curve (AUC) of free insulin for every period of 1 hour and for 
every interval from the injection up to the total period of 8 hours 
(cumulative AUCs) were calculated for every curve with the method of 
addition of trapezia. The number of counts after a certain time period 
(expressed as percentage of the initial number) was correlated with 
the cumulative AUC of free insulin for the same period (expressed as 
percentage of the total AUC) using Spearman's correlation coeffi­
cients. For both injection techniques the intraindividual variation at 
every time point was calculated for each of the measured parameters 
and expressed in an intraindividual standard deviation (SD). These in­
traindividual SDs were compared using Wilcoxon's signed rank test. 
RESULTS 
1. 24-Hour plasma profiles of free insulin and glucose in type 1 
diabetic patients, using a basal-prandi al injection regimen (Fig 1) 
The dose of short-acting insulin injected before breakfast varied 
between 8 and 24 U (mean 13+3 SEM), before lunch between 4 and 10 U 
(8+1) and before dinner between 6 and 18 U (10+2). The dose of inter­
mediate-acting insulin injected before the night varied between 4 and 
32 U (17+4). 
The percentual distribution of the total amount of insulin injected 
per 24 hours was 28% before breakfast, 16% before lunch and 21% before 
dinner, as regular insulin, and 35% at bedtime, as intermediate-acting 
insulin. 
Before the injection of insulin at breakfast the basal plasma free in­
sulin concentration was 13+3 μU/ml (mean _+ SEM). Peaks of free insulin 
^гее insuiin (^lU/ml ) 
80 
AR AR 
1 1 60 
¿о 
20 
AR 
1 
MT 
i 
' ^ \
ч
/"ч N i 
N I 
Glucose ( mmol/l) 
2 0 -
Typel diabetics ( N = 6 ) 
Mean t SEM 
10- І - К ^ 
J 1-
N ¡ ^ _ J _ _ _ , _ J _ ¡ _ ¿ - U / ' ^ i ~ . j _ j / ' 
-i~-í 
J^ 
τ — ι — ι — ι 1 — ι — \ — ι — ι — ι — ι — ι — ι — ι — ι — ι — ι 1 — ι — ι — ι — ι 1 — ι — ι — r 
8 Ό 12 U 16 18 20 22 24 2 4 6 β 
Insulin ( j j U / m l ) 
80 η 
60 
40 
20 
^ 
Glucose ( m m o l / l ) 
2 0 -
10-
*-4 
ι-. Λ 
Healthy volunteers (N=4) 
M e a n t SE M 
-»'•''^•-
1 Г" 
22 
— ι 1 г 
6 8 
Time (h 
10 12 16 18 20 24 
Fig. 1. Plasma glucose and free insulin concentrations (mean +^  SEM) 
during 24 hours in 6 type 1 diabetic patients using the basal-
prandial regimen of insulin injection. 
AR: injection of Actrapid, MT: injection of Monotard (upper 
panel). Meals were taken at 8.30, 12.30 a.m. and 5.30 p.m. 
(i.e. 30 minutes after the injection of insulin). 
For comparison plasma glucose and insulin concentrations in 4 
healthy volunteers taking meals at 8.00, 12.00 a.m. and 5.00 
p.m. are given in the lower panel. (From: Lutterman JA. Labie­
le en stabiele insuline-afhankelijke type 1 diabetes melli­
tus. Thesis, Nijmegen, 1982). 
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were reached after a mean time interval of 1 hour from the injection 
of the regular insulin (i.e. 30 minutes after the beginning of the 
meal) and amounted to 50+4, 47+_7 and 46+9 yU/ml, respectively. Between 
the meals a slow decrease in free insulin levels occurred but the 
basal value was not reached. During the night mean insulin concentra-
tions were between 17+5 and 10+5 ¿U/ml. 
Before the injection of insulin at breakfast the basal plasma concen-
tration of bound (i.e. total minus free) insulin in these 6 patients 
was 0, 0, 24, 35, 0 and 0 yU/ml respectively. After the injection in 
none of the patients an increase in bound insulin was found. 
2. Absorption rate, plasma insulin, C-peptide and glucose concentra-
tions and their reproducibility, after conventional injection and 
injection with an insulin pen 
a. Absorption rate of insulin (Fig 2) 
The residual amount of radioactivity, expressed as percentage of 
the number of radioactive counts measured immediately after the 
injection of insulin, is given in Fig. 2. At none of the time 
points a significant difference was found between the injection 
techniques. 
Each curve calculated by means of the given formula fitted the ex-
perimentally obtained curve. 
The mean + SD of the calculated rate constants (expressed as per-
centage per minute) did not show significant differences between 
both techniques either (K12 0.0066*0.0017 vs 0.0071+0.0036, Kj 
0.0005±0.0007 vs 0.0010±0.0017, KSp 0.0094+0.0030 vs 0.0088+ 
0.0037 conventional injection vs pen injection; NS). 
b. Plasma insulin concentration (Fig 3a) 
As after the eating of biscuits a minor increase in plasma glucose 
occurred, but no increase in plasma insulin, all of the insulin 
concentrations were used for calculations. No significant differ-
ences in plasma insulin concentration were found between both in-
jection techniques except for the value at 60 minutes after in-
jection: 31.5 +_ 2.7 μ U/ml after pen injection versus 22.0 +_ 1.6 
(mean +_ SEM) after conventional injection (p<0.05). AUCs of free 
insulin for the total 8-hour period and cumulative AUCs for every 
118 
time interval from the injection onwards were calculated and com­
pared. No significant differences were found. The correlation coef­
ficients between the decrease in radioactive counts at the injec­
tion site and the cumulative AUC for the same time period were cal­
culated in every patient. From 2 to 6 hours after injection signi­
ficant (p<0.05) correlation coefficients were found. With the con­
ventional injection technique the correlation coefficients varied 
between -0.62 and -0.97 and with pen injection between -0.71 and 
-0.98. The differences between the 2 techniques in this respect 
were not significant. 
Mean + SEM of plasma C-peptide concentrations are shown in Fig. 
3b. Immediately after injection of insulin C-peptide levels de­
creased. After 3 hours a plateau level was reached. As is evident 
from the figure no significant differences in C-peptide were found 
between the injection techniques. 
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Fig. 2 Residual radioactivity at the injection site as percentage of 
the initial number of counts (mean + SEM) for both injection 
techniques. Arrow indicates time of injection of insulin. 
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(mmol/1) concentrations (mean +_ SEM) after insulin injection 
with both techniques. Arrow indicates time of injection of 
insulin. In panel с the figures indicate the number of obser­
vations. 
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c. Plasma glucose concentration (Fig Зс) 
With the conventional injection technique a plasma glucose concen­
tration of 2.5 mmol/L or less was found during the first 2.5 hours 
after injection in 1 and after pen injection in 4 volunteers. Hypo­
glycemic symptoms, however, did not develop. Plasma glucose concen­
trations in every volunteer were used until the time biscuits were 
taken because of a plasma glucose <2.5 mmol/L. No differences in 
glucose concentrations were found between both injection techni­
ques. 
d. Reproducibility of results 
The reproducibility of the results obtained with both injection 
techniques was expressed in the intraindividual SO. For each para­
meter (residual radioactivity, plasma insulin, glucose and C-pep-
tide concentration) this intraindividual SD was calculated for 
every time point after injection. The intraindividual SD of the re­
sidual amount of radioactivity at the injection site varied between 
a minimum value of 3.7% and a maximum of 11.2% after conventional 
injection and 3.5 and 12.8% after pen injection. SDs after conven­
tional injection were significantly smaller than after pen injec­
tion (p<0.01). 
The intraindividual SD of plasma insulin varied between 3.4 and 7.7 
U/ml after conventional and 3.2 and 12.5 yU/ml after pen injection 
and the SD of plasma glucose varied between 0.22 and 0.73 mmol/L 
after conventional and 0.26 and 0.76 mmol/L after pen injection. 
The values after conventional injection again were significantly 
smaller than after pen injection (p<0.02 and p<0.01, respective­
ly). The intraindividual SD of plasma C-peptide concentrations 
varied between 0.02 and 0.08 pmol/ml after conventional and 0.04 
and 0.08 pmol/ml after pen injection (NS). 
DISCUSSION 
This study consisted of 2 parts, the first concentrating on the possi­
bility of obtaining a physiological pattern of free insulin concentra­
tions during a basal-prandial injection regimen, the second on 
possible differences in the absorption process of insulin after in­
jection with an insulin pen as compared to conventional injection. 
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Plasma profiles of free insulin and glucose in diabetic patients on a 
basal-prandial injection regimen with an insulin pen have never been 
published. To study these profiles 6 type 1 diabetic patients without 
endogenous insulin secretion were hospitalized, maintaining their time 
and dose of insulin injection and their diet. Comparison was possible 
with 4 normal subjects, who had been studied in exactly the same 
manner on another occasion. The percentual distribution of the insulin 
injected per 24 hours over the different injections was in accordance 
with previous reports (10,11). In the patients the plasma profiles of 
glucose showed few fluctuations, but were rather high, presumably 
because they injected their usual insulin doses, despite 
hospitalization. 
The plasma concentration of free insulin showed distinct peaks. On the 
average 1 hour after the injection of the regular insulin a plasma 
peak of free insulin was obtained. After the injection of the inter-
mediate-acting insulin at bedtime, stable but slightly elevated plasma 
concentrations of free insulin were obtained. The largest difference 
between the insulin concentrations in healthy man and in the diabetic 
patients on a basal-prandial injection regimen was found in the 
insulin concentrations during the day. In contrast with the narrow 
insulin peaks in the physiological situation, a less steep increase 
and decrease in insulin concentration was found after injection of 
regular insulin. Between the injections the basal level was not 
reached. Thus, it appears that abdominal injection with the insulin 
pen according to a basal-prandial regimen can cause stable glucose 
levels and probably even near-normoglycemia, but only at the expense 
of a considerable hyperinsulinemia. A basal-prandial regimen of 
insulin injection thus differs in this important respect from the 
physiological situation. Subcutaneous injection of new shorter-acting 
insulins (12) as the prandial part of a basal-prandial regimen offers 
prospects of obtaining near-normoglycemia while simultaneously dimin-
ishing hyperinsulinemia. 
In the second part of this study the possibility of differences in 
insulin absorption rate, increase in plasma levels of insulin and de-
crease in plasma glucose levels after conventional deep subcutaneous 
injection and injection with an insulin pen was investigated in 10 
healthy volunteers. Both injection techniques were employed twice. 
With both techniques a similar suppression of endogenous insulin se-
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cretion was obtained as appears from the decrease in C-peptide concen-
tration. No significant differences were found in absorption rate and 
mean plasma glucose concentrations. Mean insulin concentrations after 
injection with the two techniques were only significantly different 60 
minutes after the injection. No significant differences were found in 
the area under the curve of insulin or in the other parameters. We, 
therefore, conclude that the difference in insulin concentration found 
60 minutes after injection is of little practical importance. 
The variability in the studied parameters after pen injection was sig-
nificantly larger than after conventional injection, although the dif-
ferences were small. This is surprising because of the good reprodu-
cibility of the injected dose with pen injection. The standardization 
of the conventional injection technique perhaps has minimized the 
variability in the parameters after this technique, whereas the 
lifting of a skinfold in the patients with a thin subcutaneous fat 
layer when injecting with the pen could have introduced a source of 
variability with this technique. 
In conclusion, a basal-prandial injection regimen with an insulin pen 
only partly imitates the physiological pattern of free insulin concen-
trations, as a substantial hyperinsulinemia remains. Injection with an 
insulin pen, moreover, does not cause an important acceleration in the 
absorption of insulin but rather a larger variability in absorption 
rate. 
It has become clear, however, that a better metabolic regulation can 
be obtained in insulin-dependent diabetic patients using an insulin 
pen in a basal-prandial injection regimen. Thus, the larger variabili-
ty in absorption rate we found, probably can be matched by adaptating 
time and dose of the injected insulin, which can easily be performed 
with this device. 
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SUMMARY 
The aim of the treatment of diabetic patients is to achieve and main-
tain normoglycaemia. In relation to type 1 (insulin-dependent) diabe-
tes mellitus this means that knowledge of the absorption process of 
subcutaneously injected insulin and the circumstances that influence 
the absorption rate is important. A reproducible and fast absorption 
of subcutaneously injected regular insulin is necessary to obtain nor-
moglycaemia. The absorption rate of regular insulin after subcutaneous 
injection and its variability under various circumstances are the sub-
jects of this thesis. 
In chapter I the feasible methods to investigate the absorption pro-
cess of subcutaneously injected insulin are dealt with. Emphasis lays 
on the method labelled insulin is injected and the radioactivity at 
the injection site is measured. The disappearance of radioactivity can 
be taken as a measure for insulin absorption, provided that three con-
ditions have been met. The first and second conditions are that 
labelled insulin behaves like unlabelled insulin throughout the ab-
sorption process and that externally measured radioactivity reflects 
the amount of insulin not yet absorbed. The third condition, that 
labelled and unlabelled insulin are not degraded in the subcutaneous 
tissue layers, has been disputed. The pros and cons are summarized and 
it is concluded that subcutaneous degradation of insulin, if existent 
at all, is not an important problem in most diabetic patients. Thus, 
external counting of radioactivity is a valid method to study the ab-
sorption of insulin. The mechanisms presumably playing a role in the 
absorption process are discussed, for example subcutaneous blood flow, 
désintégration of insulin hexamers into monomers and diffusion of 
insulin towards the capillaries. A review is given of the factors with 
a known influence on the absorption rate, classified according to 
insulin preparation, method of administration and patient factors. The 
influence of several factors has not yet been elucidated, for example 
technique and depth of injection, presence of insulin antibodies and 
the role of absorption in the etiology of brittle diabetes. The aim of 
this thesis is to investigate the influence of these factors. 
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In chapter II the technical methods used in the absorption studies are 
described. In order to allow a reproducible injection at an indivi-
dualized depth between subcutaneous fat and muscle layers it was ne-
cessary to measure the thickness of the skin and fat layer accurate-
ly. Ultrasonic measurement of the skin layers was developed and its 
results were compared with those of the commonly used skinfold 
measurement. In the first paragraph of this chapter the ultrasonic 
technique is described. Systematic differences in measurement results 
or reproducibility were not found between ultrasound and skinfold 
technique, but ultrasound appeared to be applicable in every subject, 
in contrast with the skinfold measurement. Furthermore, a technical 
device was developed to standardize the insulin injection technique. 
With this device insulin is injected at a fixed angle between needle 
and skin, while the depth of injection can be determined accurately. 
The last paragraph describes the technical aspects of the measurement 
of radioactivity and the radiation load to the participants after the 
injection of l25I-labelled human regular insulin. The calculated 
radiation load corresponds to the naturally occurring background 
radioactivity during 4 days. 
The disappearance of radioactivity after subcutaneous injection of 
125i_ labelled insulin is expressed in the literature as T50: the time 
until half of the radioactivity has disappeared from the injection 
site. These disappearance curves are characterized by a slow initial 
phase, a faster second phase and a slow terminal phase. For a more 
adequate description of these curves three mathematical formulas have 
been developed in chapter III, based on three different concepts of 
the absorption process: a diffusion rate-limited concept, a dissolu-
tion rate-limited concept and a capacity-limited concept. The dis-
appearance curves after subcutaneous injection of labelled human 
regular insulin in healthy volunteers were fitted with these three 
models. For each curve and model goodness of fit (R2) and sum of 
weighted squared deviations (SWSOs) were calculated. The fitting 
results with each of the models were satisfying. The SWDSs with the 
second model, however, were less satisfactory than with the first and 
third model because this model cannot describe the initial phase ade-
quately. When volume and concentration of the injected insulin were 
varied, the parameters of the first and third model also varied, 
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arguing against the validity of these models. It is concluded that 
each of the three models, although yielding a good description of the 
observed data, is too simple conceptually. Suggestions for more appro-
priate modelling are given. 
The aim of the studies described in chapter IV is to measure the ab-
sorption rate of insulin and its variability in healthy volunteers and 
in different groups of diabetic patients. After injection of 8 U of 
125i-iabelled regular insulin a significant correlation between de-
crease in radioactivity at the injection site and increase in free in-
sulin concentration in plasma was found, indicating that the method of 
external counting of radioactivity is valid. Using a standardized in-
jection technique no differences in absorption rate were found between 
healthy volunteers, matched type 1 diabetics and brittle type 1 dia-
betics. A less standardized injection technique (the patients own 
skinfold technique) did not appear to influence the absorption rate. 
When standardized deep injection was compared with superficial injec-
tion, no differences were found in absorption rate, plasma free in-
sulin and glucose concentrations. The variability within subjects of 
the absorption rate was not larger in the diabetic groups than in the 
healthy subjects, but the variability between subjects was larger in 
diabetic patients. There remains a possibility that this is caused by 
differences in metabolic regulation. We conclude that the absorption 
rate of insulin is not different between healthy and diabetic subjects 
and is not influenced by injection technique or depth of injection. As 
the variability within subjects is not larger in brittle than in 
stable diabetics, a variable absorption could not be demonstrated as a 
cause of brittle diabetes in our group of patients. 
Treating diabetic patients with subcutaneously injected insulin in-
duces the production of insulin antibodies. These antibodies are known 
to influence insulin pharmacokinetics. Chapter V describes a study in 
which the influence of insulin antibodies on absorption rate of 
insulin and on plasma concentrations of free insulin and glucose is 
investigated. We selected two groups of insulin-treated diabetic 
patients, the first containing 9 diabetics without insulin antibodies 
and the second 14 patients with very high concentrations of anti-
bodies, and we measured insulin absorption rate, free insulin and 
128 
glucose after injection of 125i_i
a
belled regular insulin. Despite a 
maximum difference in antibody concentration no differences in the 
studied variables were found. Our conclusion is that the presence of 
insulin antibodies is not of clinical importance. 
A new device for subcutaneous injection of insulin, the insulin pen, 
has been introduced. This pen is usually employed in a basal-prandial 
injection regimen in order to obtain more physiological plasma insulin 
concentrations than with conventional regimens. The ultimate goal of a 
basal-prandial regimen is, of course, to achieve normoglycaemia. In 
chapter VI two studies in which the use of an insulin pen is evaluated 
are described. The first is concerned with the question whether really 
physiological free insulin levels are obtained when using an insulin 
pen in a basal-prandial regimen. In б type 1 diabetic patients, how­
ever, much higher concentrations of free insulin were found than in 
healthy volunteers. Apparently normoglycaemia can only be obtained at 
the expense of a considerable hyperinsulinaemia. In the second study 
the absorption rate of 125i-iabelled insulin was measured in 10 heal­
thy volunteers after injection with a pen and after injection with a 
conventional syringe and needle. Differences in absorption rate and 
plasma glucose were not found. Plasma insulin concentrations were only 
significantly different at 60 minutes after injection. We conclude 
that injection with a pen causes no clinically significant differences 
as compared with conventional injection. 
Even under standardized conditions, considerable intra- and inter-
individual differences in absorption rate of insulin remain. Variation 
in injection technique (skinfold technique, pen injection) or depth of 
injection does not influence the absorption rate. An influence of 
insulin antibodies on absorption rate and on plasma free insulin con­
centration was not found, nor was there an indication that brittleness 
of diabetes is caused by variability of absorption. The intra- and 
interindividual variability, therefore, must be caused by other 
factors. Although the exact mechanisms involved in the absorption 
process are unknown, it has been described that insulin absorption 
correlates well with subcutaneous blood flow. The exact role of the 
subcutaneous blood flow in the variability of insulin absorption, 
however, remains to be elucidated. 
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SAMENVATTING 
Bij de behandeling van diabetespatiënten wordt tegenwoordig algemeen 
gestreefd naar normoglycaemie. Dit betekent dat bij patiënten met type 
I (van insuline afhankelijke) diabetes mellitus kennis van het proces 
van absorptie van subcutaan geïnjicieerde insuline en van de factoren 
die de absorptiesnelheid beïnvloeden van belang is. Om normoglycaemie 
te bereiken is namelijk een snelle en reproduceerbare absorptie van 
insuline nodig. De absorptiesnelheid van subcutaan toegediende, kort-
werkende insuline onder verschillende omstandigheden is het onderwerp 
van dit proefschrift. 
In hoofdstuk I worden de methoden besproken die gebruikt kunnen worden 
om het absorptieproces van onderhuids geïnjicieerde insuline te onder-
zoeken. De nadruk wordt gelegd op de methode waarbij radioactief ge-
merkt insuline wordt ingespoten en de radioactiviteit op de injectie-
plaats vervolgd wordt. Het verdwijnen van radioactiviteit kan als maat 
voor de insulineabsorpt,e genomen worden, mits aan drie voorwaarden is 
voldaan. Deze voorwaarden zijn, dat gelabelde insuline zich tijdens 
het hele absorptieproces hetzelfde gedraagt als ongelabelde en dat de 
uitwendig gemeten radioactiviteit een maat is voor de nog niet geab-
sorbeerde hoeveelheid insuline. De derde voorwaarde, namelijk dat ge-
labelde en ongelabelde insuline niet afgebroken worden in het subcuta-
ne vetweefsel, is vaak bekritiseerd. De argumenten voor en tegen wor-
den in dit hoofdstuk samengevat. Geconcludeerd wordt dat subcutane af-
braak van insuline, zo die al bestaat, bij het merendeel van de diabe-
tespatiënten geen groot probleem vormt. Uitwendig meten van radioacti-
viteit na injectie van gelabelde insuline is dus een deugdelijke me-
thode om de absorptie van insuline te bestuderen. 
De processen die een rol spelen bij de absorptie, zoals de subcutane 
circulatie, het uiteenvallen van insuline-hexameren in monomeren en 
de diffusie van insuline naar de capillairen, worden besproken. Ver-
volgens wordt een overzicht gegeven van de factoren waarvan de invloed 
op de absorptiesnelheid bekend is. Een indeling is gemaakt naar van 
het insulinepreparaat afhankelijke, van de wijze van toediening afhan-
kelijke en van de patiënt afhankelijke factoren. De invloed van enkele 
van deze factoren is echter nog niet duidelijk, bijvoorbeeld van tech-
niek en diepte van injectie en van de aanwezigheid van insulineantili-
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chamen. De rol van de absorptie bij het ontstaan van de labiele vorm 
van diabetes is evenmin bekend. 
Het doel van dit onderzoek is de invloed van deze factoren na te gaan. 
In hoofdstuk II worden de methoden beschreven die bij het onderhavige 
onderzoek naar de insuline-absorptie werden gebruikt. Om een reprodu-
ceerbare injectie op een individueel bepaalde diepte mogelijk te maken 
is het nodig om de dikte van huid en vetlaag nauwkeurig te meten. Een 
echografische methode om de huidlagen te meten werd ontwikkeld en de 
resultaten daarvan werden vergeleken met die van de gewoonlijk ge-
bruikte huidplooi-meetmethode. In de eerste paragraaf van dit hoofd-
stuk wordt de echografische methode beschreven. Er werden geen syste-
matische verschillen in de meetresultaten of de reproduceerbaarheid 
van beide methoden gevonden. De echografie bleek echter wel bij iedere 
persoon toepasbaar te zijn, in tegenstelling tot de huidplooimethode. 
Verder werd een hulpstukje ontworpen om de techniek van de insuline-
injectie te standaardiseren. Met dit hulpstukje wordt insuline geïnji-
cieerd onder een vaste hoek tussen naald en huid, terwijl de diepte 
van injectie precies bepaald kan worden. De laatste paragraaf be-
schrijft de technische aspecten van het meten van radioactiviteit op 
de injectieplaats en de stralenbelasting voor de deelnemers aan het 
onderzoek na injectie van met 125i gelabelde humane kortwerkende insu-
line. De berekende stralenbelasting komt overeen met die tengevolge 
van de in de natuur voorkomende achtergrond-radioactiviteit gedurende 
4 dagen. 
De snelheid van het verdwijnen van radioactiviteit na subcutane injec-
tie van met 125i gelabelde insuline wordt in de literatuur uitgedrukt 
in de T50: de tijd tot de helft van de radioactiviteit van de injec-
tieplaats is verdwenen. De verdwijningscurves worden echter gekarak-
teriseerd door een trage inloopfase, een snellere tweede fase en weer 
een trage eindfase. In hoofdstuk III worden daarom drie wiskundige 
formules ontwikkeld voor een meer adequate beschrijving van deze 
curves met behulp van drie verschillende concepten van het absorptie-
proces: concepten waarin de absorptiesnelheid bepaald wordt gedacht 
door respectievelijk de snelheid van diffunderen van de insuline, de 
snelheid van oplossen van het muntvormige volume van de geïnjicieerde 
insuline, en de capaciteit van het pharmakokinetische systeem. De ver-
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dwijningscurves bij gezonde vrijwilligers werden met deze drie model-
len gefit. Voor iedere curve met ieder model werden de "goodness of 
fit" (R2)
 en de som van "dg gewogen gekwadrateerde afwijkingen" (sum 
of weighted squared deviations, SWSD) berekend. De fitresultaten waren 
met ieder model bevredigend. De SWSD's waren met het tweede model ech-
ter minder goed dan met beide andere, omdat dit model de inloopfase 
niet adequaat kan beschrijven. Wanneer volume en concentratie van de 
ingespoten insuline werden gewijzigd, varieerden de parameters van het 
eerste en het derde model ook, hetgeen pleit tegen de geldigheid van 
deze modellen. Geconcludeerd wordt dat alle drie de modellen, hoewel 
ze ieder een goede beschrijving geven van de resultaten, op te eenvou-
dige concepten berusten. Er worden suggesties gedaan voor meer ge-
schikte modellen. 
Het doel van het in hoofdstuk IV beschreven onderzoek is de absorptie-
snelheid van insuline en de variabiliteit daarvan te meten bij gezonde 
vrijwilligers en bij verschillende groepen diabetici. Na injectie van 
8 E met 125i gelabelde kortwerkende insuline werd een significante 
correlatie gevonden tussen de afname van de radioactiviteit op de in-
jectieplaats en de toename van de concentratie van vrij insuline in 
het plasma. Dit duidt erop dat de methode van uitwendig meten van 
radioactiviteit deugdelijk is. Na injectie met een gestandaardiseerde 
techniek werden geen verschillen in absorptiesnelheid gevonden tussen 
gezonde vrijwilligers, gematched type I diabetespatiënten en stabiele 
type I diabeten. Injectie met een minder gestandaardiseerde techniek, 
te weten de eigen techniek van de patiënt, bleek de absorptiesnelheid 
niet te beïnvloeden. Wanneer op gestandaardiseerde wijze verrichte, 
diepe injectie werd vergeleken met oppervlakkige injectie, werden geen 
verschillen gevonden in absorptiesnelheid en in concentraties van vrij 
insuline en glucose in het plasma. 
De intraindividuele variabiliteit van de absorptiesnelheid was niet 
groter bij de diabetespatiënten dan bij de gezonde vrijwilligers, maar 
de interindividuele variabiliteit was dat wel. Het is mogelijk dat dit 
verschil wordt veroorzaakt door verschillen in metabole instelling. 
Wij concluderen dat de absorptiesnelheid van insuline niet wordt beïn-
vloed door techniek of diepte van injectie. Aangezien de intraindivi-
duele variabiliteit niet groter is bij patiënten met een labiele vorm 
van diabetes dan bij patiënten met een stabiele vorm, konden in onze 
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patiëntengroep verschillen in absorptie niet als oorzaak van de labi-
liteit worden aangemerkt. 
Het behandelen van diabetespatiënten met subcutaan ingespoten insuline 
veroorzaakt de vorming van insulineantilichamen. Van deze anti lichamen 
is een invloed bekend op de farmakokinetiek van insuline. Hoofdstuk V 
beschrijft een onderzoek waarin de invloed van de aanwezigheid van in-
sul ineantilichamen op de absorptiesnelheid en op de concentraties van 
vrij insuline en glucose in het plasma wordt bestudeerd. Wij selec-
teerden twee groepen met insuline behandelde diabetespatiënten. Aan de 
eerste groep namen 9 diabetici zonder insulineantilichamen deel, aan 
de tweede groep 14 patiënten met zeer hoge concentraties anti licha-
men. Behalve de absorptiesnelheid van insuline werden ook de concen-
traties vrij insuline en glucose in het plasma gemeten na injectie van 
met 125i gelabelde kortwerkende insuline. Ondanks een maximaal ver-
schil in anti lichaam-concentratie werden geen verschillen gevonden in 
de onderzochte parameters. Onze conclusie is dan ook dat de aanwezig-
heid van insulmeantilichamen niet van klinische betekenis is. 
Recent werd een nieuw hulpmiddel geïntroduceerd voor de injectie van 
insuline: de insulinepen. Een dergelijke pen wordt meestal gebruikt 
voor een basaal-prandiaal injectieschema om op die manier meer fysio-
logische insulineconcentraties in het plasma te verkrijgen dan met 
conventionele injectieschema's. Het uiteindelijke doel van een 
basaal-prandiaal schema is het bereiken van normoglycaemie. In hoofd-
stuk VI worden twee onderzoeken beschreven waarin het gebruik van een 
insulinepen wordt onderzocht. Het eerste gaat over de vraag of werke-
lijk fysiologische concentraties vrij insuline in het plasma worden 
bereikt wanneer een insulinepen wordt gebruikt in een basaal-prandiaal 
injectieschema. Bij б type I diabetespatiënten werden echter veel ho-
gere concentraties vrij insuline gemeten dan bij gezonde vrijwilli-
gers. Blijkbaar kan normoglycaemie slechts worden bereikt ten koste 
van een aanzienlijk hypennsulinisme. In het tweede onderzoek werd de 
absorptiesnelheid van met 125i gelabelde insuline gemeten bij 10 ge-
zonde vrijwilligers na injectie met een pen en na injectie met een 
conventionele naald en spuit. Er werden geen verschillen gevonden in 
absorptiesnelheid en in glucosespiegels in het plasma. De insulinecon-
centraties in het plasma verschilden alleen significant tussen beide 
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technieken 60 minuten na de injectie. Wij concluderen dat injectie met 
een pen geen klinisch significante verschillen veroorzaakt met conven-
tionele injectie. 
Zelfs onder gestandaardiseerde omstandigheden blijven er aanzienlijke 
intra- en intermdividuele verschillen in absorptiesnelheid van insu-
line bestaan. Verschillen in injectietechniek (huidplooitechmek, in-
jectie met een pen) of diepte van injectie beïnvloeden de absorptie-
snelheid niet. Een invloed van insuline-antilichamen op de absorptie-
snelheid werd niet gevonden en een indicatie dat labiliteit van de 
metabole instelling van de diabetes wordt veroorzaakt door variabili-
teit in absorptie, evenmin. De intra- en intermdividuele variabili-
teit moet daarom door andere factoren worden veroorzaakt. Hoewel de 
mechanismen die bij het absorptieproces betrokken zijn niet precies 
bekend zijn, is het beschreven dat de insulineabsorptie goed corre-
leert met de subcutane doorbloeding. De precieze rol van de subcutane 
doorbloeding bij de variabiliteit van de insulineabsorptie moet echter 
nog opgehelderd worden. 
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Stellingen 
1. Bij het streven naar normoglycaemie bij patiënten met van insuline 
afhankelijke diabetes mellitus is kennis van de factoren die de ab-
sorptie van subcutaan toegediende insuline beïnvloeden, onontbeer-
lijk. 
2. De door Binder beschreven methode voor het bestuderen van de ab-
sorptie van insuline is deugdelijk. 
3. Noch de techniek van subcutane injectie van insuline, noch de diep-
te van injicieren, is van belang voor de snelheid van de absorptie. 
4. Labiliteit van de metabole regulatie bij van insuline afhankelijke 
diabeten wordt m e t veroorzaakt door een grotere variabiliteit in 
de absorptie van insuline. 
5. De absorptie van subcutaan toegediende insuline verloopt m e t aan-
toonbaar verschillend tussen diabetespatiënten met hoge en met lage 
concentraties insul meant 111 chamen. 
6. Diabeteseducatie blijft voor de patient zonder rendement wanneer 
deze m e t wordt gecontinueerd. 
7. Wil de verwijzing van een patient door de huisarts naar de inter-
nist een vorm van samenwerken zijn, dan moeten beiden zich actief 
op de hoogte stellen van eikaars wijze van werken. 
P.J.R. Mesker, 
in: С van Weel, S.A. Danner (red.), 
Huisarts en internist. Utrecht 1984. 
8. Ongeacht de diagnose, mag bij geen enkele geriatrische patient be­
wegingstherapie achterwege worden gelaten. 
9. Een afwijkende medische bevinding zonder therapeutische of prognos­
tische consequenties is geen diagnose. 
10. De resultaten van genealogisch onderzoek kunnen alleen dan van 
meer dan strict persoonlijke betekenis zijn, wanneer ze in hun 
samenhang met de locale geschiedenis worden beschouwd. 
11. Whoever can make two ears of corn or two blades of grass to grow 
upon a spot of ground where only one grew before, deserves better 
of mankind than the whole race of politicians put together. 
Naar Jonathan Swift, 
Gulliver's Travels. 
12. Onderzoek naar de bedijkingsactiviteiten van particulieren naast 
die van Vlaamse monniken en Staatse militairen, kan het inzicht in 
het totstandkomen van het huidige Zeeuwsch-Vlaanderen ingrijpend 
wijzigen. 
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